TYK2 pseudokinase ligand

Abstract

Described herein are TYK2 pseudokinase ligands and methods of utilizing the TYK2 pseudokinase ligands in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Description

[Technical field]

[0001] cross reference This application claims the benefit of U.S. Provisional Application No. 62 / 933,179, filed November 8, 2019, and U.S. Provisional Application No. 63 / 046,514, filed June 30, 2020, both of which are incorporated herein by reference. [Background technology]

[0002] Janus kinases (JAKs) are a family of intracellular non-receptor tyrosine kinases that transduce cytokine-mediated signals through the JAK-STAT pathway. Four JAK family members, Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2), have been recognized as key components of cytokine-mediated actions. Unlike JAK1-deficient mice, TYK2-deficient mice are viable, and TYK2 deficiency has been shown to be protective in various autoimmune models. Summary of the Invention

[0003] In one aspect, provided herein is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof:

[0004] [ka] During the ceremony, X is N or C(R6); Y is C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 aryl, C2-C9 heteroaryl, or

[0005] [ka] and C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C10 Aryl, or C2-C9 heteroaryl is optionally substituted by 1, 2, 3, or 4 R7; L1 is a single bond, -O-, -C(O)-, -N(R9)-, -N(R9)CH2-, or -CH2N(R9)-; R1 can be 1, 2, or 3 R 13 is a C3-C6 cycloalkyl substituted with R2, R3, and R4 are independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; R5 is hydrogen or C1-C6 alkyl; each R6 is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; Each R7 is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, C2-C9 heteroaryl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11 , -S(=O)2R 11 , and -S(=O)2N(R 10 )2, selected from C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl and C2-C9 heteroaryl are halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12or two R7 combined to form a 5-, 6-, or 7-membered heterocycloalkyl ring or a 4-, 5-, or 6-membered cycloalkyl ring; R8 is hydrogen, deuterium, halogen, C1-C6 alkyl, or C1-C6 deuteroalkyl; R9 is hydrogen or C1-C6 alkyl; Each R 10 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, and phenyl, where phenyl is selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 Optionally substituted with 1, 2, or 3 groups selected from Each R 11 is independently selected from C1-C6 alkyl and C1-C6 heteroalkyl; Each R 12 is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; Each R 13 are independently selected from halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, C2-C9 heteroaryl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11 , -S(=O)2R11 , and -S(=O)2N(R 10 )2, selected from C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl and C2-C9 heteroaryl are halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 Optionally substituted with 1, 2, or 3 groups selected from n is 0, 1, 2, 3, or 4.

[0006] In some embodiments, Y is a C6-C optionally substituted with 1, 2, or 3 R7. 10 In some embodiments, the compound of formula (I') is a phenyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is a C2-C9 heteroaryl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is a C2-C9 heteroaryl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') or a pharmaceutically acceptable salt or solvate thereof, wherein Y is a C2-C9 heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl are optionally substituted by 1, 2, or 3 R7. In some embodiments, Y is

[0007] [ka] In some embodiments, the compound of formula (I') is, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is, or a pharma- ceutically acceptable salt or solvate thereof, where n is 0, 1, or 2. In some embodiments, the compound of formula (I') is, or a pharma- ceutically acceptable salt or solvate thereof, where each R7 is independently selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, Y is

[0008] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0009] [ka] In some embodiments, each R is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof. 13 is independently selected from halogen, -OH, -CN, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, and oxo, or a pharma- ceutically acceptable salt or solvate thereof. 13 is independently selected from halogen, -OH, and -CN, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R is one R 13 or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R is cyclopropyl substituted with one or two R 13or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is a compound of formula (I'), wherein R1 is cyclobutyl optionally substituted by

[0010] [ka] In some embodiments, the compound of formula (I') is a phenyl group, or a pharma- ceutically acceptable salt or solvate thereof. ... In some embodiments, the compound is of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where R6 is hydrogen. In some embodiments, the compound is of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where R8 is hydrogen. In some embodiments, the compound is of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where R2 is hydrogen. In some embodiments, the compound is of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where R5 is hydrogen. In some embodiments, the compound is of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where X is N. In some embodiments, the compound is of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(R6). In some embodiments, the compound is of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(H).

[0011] In another aspect, provided herein is a compound of Formula (I) or Formula (II), or a pharma- ceutically acceptable salt or solvate thereof:

[0012] [ka]

[0013] [ka] During the ceremony, X is N or C(R6); Y is C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 aryl, C2-C9 heteroaryl, or

[0014] [ka] and C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, or C2-C9 heteroaryl is optionally substituted by 1, 2, 3, or 4 R7; L1 is a single bond, -O-, -C(O)-, -N(R9)-, -N(R9)CH2-, or -CH2N(R9)-; R1 is selected from hydrogen, deuterium, C1-C6 alkyl, C1-C6 deuteroalkyl, C3-C6 cycloalkyl, -C1-C6 alkyl-C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, and C2-C9 heteroaryl, where C1-C6 alkyl, C3-C6 cycloalkyl, -C1-C6 alkyl-C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, or C2-C9 heteroaryl is optionally substituted by 1, 2, or 3 R7; R2, R3, and R4 are independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; R5 is hydrogen or C1-C6 alkyl; each R6 is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; Each R7 is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, C2-C9 heteroaryl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11 , -S(=O)2R 11 , and -S(=O)2N(R 10 )2, selected from C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl and C2-C9 heteroaryl are halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 or two R7 combined to form a 5-, 6-, or 7-membered heterocycloalkyl ring or a 4-, 5-, or 6-membered cycloalkyl ring; R8 is hydrogen, deuterium, halogen, C1-C6 alkyl, or C1-C6 deuteroalkyl; R9 is hydrogen or C1-C6 alkyl; Each R 10is independently selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, and phenyl, where phenyl is selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 Optionally substituted with 1, 2, or 3 groups selected from Each R 11 is independently selected from C1-C6 alkyl and C1-C6 heteroalkyl; Each R 12 is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; and n is 0, 1, 2, 3, or 4.

[0015] In some embodiments, the compound is of formula (I), or a pharma- ceutically acceptable salt or solvate thereof.

[0016] [ka]

[0017] In some embodiments, the compound is of formula (II), or a pharma- ceutically acceptable salt or solvate thereof.

[0018] [ka]

[0019] In some embodiments, Y is a C6-C optionally substituted with 1, 2, or 3 R7. 10In some embodiments, the compound of formula (I) or (II) is aryl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I) or (II) is phenyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I) or (II) is C2-C9 heteroaryl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I) or (II), or a pharma- ceutically acceptable salt or solvate thereof, is selected from the group consisting of oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl are optionally substituted by 1, 2, or 3 R7. In some embodiments, the compound of formula (I) or (II), or a pharma- ceutically acceptable salt or solvate thereof, is selected from the group consisting of oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl ...

[0020] [ka] In some embodiments, the compound is of formula (I) or (II), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 0, 1, or 2. In some embodiments, the compound is of formula (I) or (II), or a pharma- ceutically acceptable salt or solvate thereof, wherein n is 0, 1, or 2. In some embodiments, the compound is of formula (I) or (II), or a pharma- ceutically acceptable salt or solvate thereof, wherein each R7 is independently selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, Y is

[0021] [ka] In some embodiments, Y is a compound of formula (I) or (II), or a pharma- ceutically acceptable salt or solvate thereof.

[0022] [ka] In some embodiments, R1 is a compound of formula (I) or (II), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is hydrogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C3-C6 cycloalkyl, -C1-C6 alkyl-C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, and C2-C9 heteroaryl, wherein C1-C6 alkyl, C3-C6 cycloalkyl, -C1-C6 alkyl-C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, or C2-C9 heteroaryl is optionally substituted by 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is a compound of formula (I) or (II), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is hydrogen. In some embodiments, R1 is a C1-C6 alkyl optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is an unsubstituted C1-C6 alkyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is a C3-C6 cycloalkyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is an unsubstituted C3-C6 cycloalkyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is an unsubstituted C3-C6 cycloalkyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is a C2-C9 heterocycloalkyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is a C2-C9 heterocycloalkyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (I) or (II), or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is a C2-C9 heteroaryl optionally substituted with 1, 2, or 3 R7.

[0023] In another aspect, provided herein is a compound of formula (III) or formula (IV), or a pharma- ceutically acceptable salt or solvate thereof:

[0024] [ka]

[0025] [ka] During the ceremony, X is N or C(R6); Y is C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, or C2-C9 heteroaryl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, or C2-C9 heteroaryl is optionally substituted with 1, 2, 3, or 4 R7; L1 is a single bond, -O-, -C(O)-, -N(R9)-, -N(R9)CH2-, or -CH2N(R9)-; L2 is a single bond, -N(R9)-, -O-, C1-C6 alkyl, or C3-C6 cycloalkyl; Each R1 is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11 , -S(=O)2R 11 , and -S(=O)2N(R 10or two R1 combined to form a 3-, 4-, 6-, or 6-membered cycloalkyl ring or a 3-, 4-, 5-, or 6-membered heterocycloalkyl ring; R2, R3, and R4 are independently selected from hydrogen, deuterium, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, and C2-C9 heterocycloalkyl; R5 is hydrogen or C1-C6 alkyl; each R6 is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; Each R7 is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, C2-C9 heteroaryl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11 , -S(=O)2R 11 , and -S(=O)2N(R 10 )2, selected from C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl and C2-C9 heteroaryl are halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12or two R7 combined to form a 5-, 6-, or 7-membered heterocycloalkyl ring or a 4-, 5-, or 6-membered cycloalkyl ring; R8 is hydrogen, deuterium, halogen, C1-C6 alkyl, or C1-C6 deuteroalkyl; R9 is hydrogen or C1-C6 alkyl; Each R 10 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, and phenyl, where phenyl is selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 Optionally substituted with 1, 2, or 3 groups selected from Each R 11 is independently selected from C1-C6 alkyl and C1-C6 heteroalkyl; Each R 12 is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; and p is 0, 1, 2, 3, or 4.

[0026] In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof.

[0027] [ka]

[0028] In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof.

[0029] [ka]

[0030] In some embodiments, Y is a C6-C optionally substituted with 1, 2, or 3 R7. 10 In some embodiments, the compound of formula (III) or (IV) is aryl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) or (IV) is phenyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) or (IV) is C2-C9 heteroaryl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) or (IV) is R7 selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) or (IV) is aryl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) or (IV) is phenyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) or (IV) is C2-C9 heteroaryl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof.

[0031] [ka] In some embodiments, the compound is a compound of formula (III) or (IV), or a pharma- ceutically acceptable salt or solvate thereof, selected from the group consisting of: In some embodiments, the compound is a compound of formula (III) or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which each R1 is hydrogen; In some embodiments, the compound is a compound of formula (III) or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which p is 1; In some embodiments, the compound is a compound of formula (III) or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which p is 2; In some embodiments, the compound is a compound of formula (III) or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which p is 0; In some embodiments, the compound is a compound of formula (III) or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which L2 is a single bond; In some embodiments, the compound is a compound of formula (III) or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which L2 is -O-; In some embodiments, the compound of formula (III) or (IV), or a pharma- ceutically acceptable salt or solvate thereof, is L2 is C1-C6 alkyl. In some embodiments, the compound of formula (III) or (IV), or a pharma- ceutically acceptable salt or solvate thereof, is L2 is C3-C6 cycloalkyl.

[0032] In some embodiments, the compound is of formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which L1 is a single bond. In some embodiments, the compound is of formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which L1 is -N(H)-. In some embodiments, the compound is of formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which R3 and R4 are independently selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound is of formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which R3 is hydrogen and R4 is C1-C6 alkyl. In some embodiments, the compound is of formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which R3 is hydrogen and R4 is C1-C6 deuteroalkyl. In some embodiments, the compound is of formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which R6 is hydrogen. In some embodiments, the compound is of formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which R8 is hydrogen. In some embodiments, the compound is of formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which R2 is hydrogen. In some embodiments, the compound is of formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which R5 is hydrogen. In some embodiments, the compound is of formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, where X is N. In some embodiments, the compound is of formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(R6). In some embodiments, the compound is of formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(H).

[0033] In another aspect, described herein is a pharmaceutical composition comprising a compound of Formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, and a pharma- ceutically acceptable excipient.

[0034] In another aspect, described herein are methods of treating an inflammatory or autoimmune disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, described herein are methods of treating an inflammatory or autoimmune disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, lupus, bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, vitiligo, and atopic dermatitis.

[0035] Citation by reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0036] definition In the context of this disclosure, a number of terms shall be utilized.

[0037] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood to belong to the subject matter specified in the invention. In the event of multiple definitions of terms herein, the definitions in this section prevail. All patents, patent applications, publications, and published nucleotide and amino acid sequences (e.g., sequences available in databases such as GenBank) cited herein are incorporated by reference. When reference is made to a URL or other identifier or address, it is understood that such identifiers may change and that particular information on the Internet may come and go, but that equivalent information may be found by an Internet search. Reference thereto acknowledges the availability and public dissemination of such information.

[0038] It is to be understood that the foregoing general description and the following detailed description are exemplary and illustrative only and are not intended to be limiting of the invention as defined by the claims. In this application, the use of the singular includes the plural unless expressly stated otherwise. It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and / or" unless expressly stated otherwise. Furthermore, the use of the term "including" is open-ended, as are other forms such as "include," "includes," "included," and the like.

[0039] The section headings used herein are for organizational purposes only and should not be construed as limiting the particular subject matter described.

[0040] Definitions of standard chemical terms can be found in references including, but not limited to, Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4TH ED." Vols. A (2000) and B (2001), Plenum Press, New York. Unless otherwise specified, conventional methods are mass spectroscopy, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques, and pharmacology.

[0041] Unless specific definitions are given, the nomenclature adopted in connection with analytical chemistry, organic synthetic chemistry, and medicinal and pharmaceutical chemistry described herein, and the procedures and techniques for testing them, are art-recognized. Standard techniques can be used for chemical synthesis, chemical analysis, pharmaceutical preparation, formulation, and delivery, and patient treatment. Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Reaction and purification techniques can be performed as commonly accomplished in the art, for example, using kits per manufacturer's specifications, or as described herein. The techniques and procedures described above can generally be performed by conventional methods and as described in various general and more specific references cited and discussed throughout this specification.

[0042] It is understood that the methods and compositions described herein are not limited to the particular methods, protocols, cell lines, constructs, and reagents described herein, and as such may vary. It is also understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the methods, compounds, and compositions described herein.

[0043] As used herein, C1-C x is C1-C2, C1-C3...C1-C x Includes: C1-C xrefers to the number of carbon atoms that make up the moiety it designates (excluding optional substituents).

[0044] An "alkyl" group refers to an aliphatic hydrocarbon group. The alkyl group may or may not contain units of unsaturation. The alkyl moiety may be a "saturated alkyl" group, meaning that the alkyl moiety does not contain units of unsaturation (i.e., carbon-carbon double bonds or carbon-carbon triple bonds). The alkyl group may further be an "unsaturated alkyl" moiety, meaning that the alkyl group contains at least one unit of unsaturation. The alkyl moiety may be saturated or unsaturated, branched or straight chain.

[0045] An "alkyl" group may have 1 to 6 carbon atoms (wherever alkyl appears herein, a number range such as "1 to 6" refers to each integer within the given range. For example, "1 to 6 carbon atoms" means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to 6 carbon atoms, but this definition also encompasses the occurrence of the term "alkyl" when no number range is specified). The alkyl group of the compounds described herein may be designated as "C1-C6 alkyl" or a similar designation. By way of example only, "C1-C6 alkyl" indicates that there are 1 to 6 carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, iso-pentyl, neo-pentyl, and hexyl. The alkyl group may be substituted or unsubstituted. The alkyl group may be a monoradical or a diradical (alkylene group) depending on the structure.

[0046] "Alkoxy" refers to the group "-O-alkyl", where alkyl is as defined herein.

[0047] The term "alkenyl" refers to a type of alkyl group in which the first two atoms of the alkyl group form a double bond that is not part of an aromatic group. That is, an alkenyl group begins with the atom -C(R)=CR2, where R refers to the remainder of the alkenyl group, which may be the same or different. Non-limiting examples of alkenyl groups include -CH=CH2, -C(CH3)=CH2, -CH=CHCH3, -CH=C(CH3)2, -C(CH3)=CHCH3. The alkenyl portion may be branched, straight chain, or cyclic (in all cases, understood as a "cycloalkenyl" group). An alkenyl group may have 2-6 carbons. An alkenyl group may be substituted or unsubstituted. An alkenyl group may be a monoradical or a diradical (alkenylene group) depending on the structure.

[0048] The term "alkynyl" refers to a type of alkyl group in which the first two atoms of the alkyl group form a triple bond. That is, an alkynyl group begins with the atom -C≡CR, where R refers to the remainder of the alkynyl group. Non-limiting examples of alkynyl groups include -C≡CH, -C≡CCH3, -C≡CCH2CH3, -C≡CCH2CH2CH3. The "R" portion of the alkynyl moiety may be branched, straight chain, or cyclic. Alkynyl groups may have 2-6 carbons. Alkynyl groups may be substituted or unsubstituted. Alkynyl groups may be monoradicals or diradicals (alkynylene groups) depending on the structure.

[0049] "Amino" refers to the group -NH2.

[0050] The term "alkylamine" or "alkylamino" refers to -N(alkyl) x H y "Dialkylamino" refers to the -N(alkyl)2 group, where alkyl is as defined herein, and x and y are selected from the group x=1, y=1, and x=2, y=0. When x=2, the alkyl groups together with the nitrogen to which they are attached can optionally form a cyclic ring system. "Dialkylamino" refers to the -N(alkyl)2 group, where alkyl is as defined herein.

[0051] The term "aromatic" refers to a planar ring having a delocalized π-electron system containing 4n+2 π electrons, where n is an integer. Aromatic rings can be formed from 5, 6, 7, 8, 9, or more atoms. Aromatics can be optionally substituted. The term "aromatic" includes both aryl (e.g., phenyl, naphthalenyl) and heteroaryl (e.g., pyridinyl, quinolinyl) groups.

[0052] As used herein, the term "aryl" refers to an aromatic ring in which the atoms forming the ring are each carbon atoms. The aryl ring can be formed by 5, 6, 7, 8, 9, or more carbon atoms. The aryl group can be optionally substituted. Examples of aryl groups include, but are not limited to, phenyl, naphthalenyl. The aryl group can be a monoradical or a diradical (arylene group) depending on the structure.

[0053] "Carboxy" refers to -CO2H. In some embodiments, the carboxy moiety may be replaced with a "carboxylic acid bioisostere," which refers to a functional group or moiety that exhibits similar physical and / or chemical properties as a carboxylic acid moiety. A carboxylic acid bioisostere has similar biological properties as a carboxylic acid group. A compound with a carboxylic acid moiety may have a carboxylic acid moiety replaced with a carboxylic acid bioisostere and has similar physical and / or biological properties compared to the carboxylic acid-containing compound. For example, in one embodiment, a carboxylic acid bioisostere ionizes to approximately the same extent as a carboxylic acid group at physiological pH. Examples of carboxylic acid bioisosteres include, but are not limited to, the following:

[0054] [ka]

[0055] The term "cycloalkyl" refers to a monocyclic or polycyclic non-aromatic radical in which the atoms forming the ring (skeletal atoms) are each carbon atoms. Cycloalkyls may be saturated or partially unsaturated. Cycloalkyls may be fused to an aromatic ring (in which case the cycloalkyl is attached via a non-aromatic ring carbon atom). Cycloalkyl groups include groups having from 3 to 10 ring atoms.

[0056] The term "heteroaryl" or, alternatively, "heteroaromatic" refers to an aryl group that contains one or more ring heteroatoms selected from nitrogen, oxygen, and sulfur. An N-containing "heteroaromatic" or "heteroaryl" moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom.

[0057] A "heterocycloalkyl" or "heteroalicyclic" group refers to a cycloalkyl group in which at least one skeletal ring atom is a heteroatom selected from nitrogen, oxygen, and sulfur. The radical may be fused to an aryl or heteroaryl. The term "heteroalicyclic" further includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides, and oligosaccharides. Unless otherwise specified, a heterocycloalkyl has 2-10 carbons in the ring. It is understood that the number of carbon atoms in a heterocycloalkyl, when referring to the number of carbon atoms in a heterocycloalkyl, is not the same as the total number of atoms (including heteroatoms) that make up the heterocycloalkyl (skeletal atoms of the heterocycloalkyl ring).

[0058] The term "halo" or alternatively "halogen" means fluoro, chloro, bromo, and iodo.

[0059] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, which can be the same or different. Non-limiting examples of haloalkyl include -CH2Cl, -CF3, -CHF2, -CH2CF3, -CF2CF3, and the like.

[0060] The terms "fluoroalkyl" and "fluoroalkoxy" include alkyl and alkoxy groups, respectively, substituted with one or more fluorine atoms. Non-limiting examples of fluoroalkyl include -CF3, -CHF2, -CH2F, -CH2CF3, -CF2CF3, -CF2CF2CF3, -CF(CH3)3, and the like. Non-limiting examples of fluoroalkoxy groups include -OCF3, -OCHF2, -OCH2F, -OCH2CF3, -OCF2CF3, -OCF2CF2CF3, -OCF(CH3)2, and the like.

[0061] The term "deuteroalkyl" refers to an alkyl group that is substituted with one or more deuteriums.

[0062] The term "heteroalkyl" refers to an alkyl radical in which one or more skeletal atoms are selected from atoms other than carbon, such as oxygen, nitrogen, sulfur, phosphorus, silicon, or combinations thereof. The heteroatoms may be located at any interior position of the heteroalkyl group. Examples include, but are not limited to, -CH2-O-CH3, -CH2-CH2-O-CH3, -CH2-NH-CH3, -CH2-CH2-NH-CH3, -CH2-N(CH3)-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2-S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH2-NH-OCH3, -CHO-Si(CH3)3, -CH2-CH=N-OCH3, and -CH=CH-N(CH3)-CH3. Additionally, up to two heteroatoms may be consecutive, such as, by way of example, -CH2-NH-OCH3 or -CH2-O-Si(CH3)3. Excluding the number of heteroatoms, a "heteroalkyl" may have 1 to 6 carbon atoms.

[0063] The term "bond" or "single bond" refers to a chemical bond between two atoms or two moieties when the atoms joined by the single bond are considered to be part of a larger substructure.

[0064] The term "moiety" refers to a specific area or functional group of a molecule. A chemical moiety is often recognized as a chemical entity that is embedded in or appended to a molecule.

[0065] As used herein, the substituent "R" occurring alone and without a number designation refers to a substituent selected from among alkyl, haloalkyl, heteroalkyl, alkenyl, cycloalkyl, aryl, heteroaryl (bonded via a ring carbon), and heterocycloalkyl.

[0066] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes examples when the event or circumstance occurs and examples when it does not occur.

[0067] The term "optionally substituted" or "substituted" means that the referenced group may be substituted with one or more additional groups independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, -OH, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, -CN, alkyne, C1-C6 alkylalkyne, halo, acyl, acyloxy, -CO2H, -CO2-alkyl, nitro, haloalkyl, fluoroalkyl, and amino, including mono- and di-substituted amino groups (e.g., -NH2, -NHR, -N(R)2), and protected derivatives thereof. As an example, an optional substituent is L s R s Each L may be s is independently selected from a single bond, -O-, -C(=O)-, -S-, -S(=O)-, -S(=O)2-, -NH-, -NHC(O)-, -C(O)NH-, S(=O)2NH-, -NHS(=O)2, -OC(O)NH-, -NHC(O)O-, -(C1-C6 alkyl)-, or -(C2-C6 alkynyl)-; sis independently selected from H, (C1-C6 alkyl), (C3-C8 cycloalkyl), aryl, heteroaryl, heterocycloalkyl, and C1-C6 heteroalkyl. Protecting groups that may form the protective derivatives of the above substituents can be found in sources such as Greene and Wuts, above.

[0068] As used herein, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.

[0069] As used herein, the term "therapeutically effective amount" refers to an amount of a TYK2 pseudokinase ligand that is effective to at least partially ameliorate or at least partially prevent a disease associated with skin aging when administered to a mammal in need thereof.

[0070] As used herein, the term "expression" includes the process by which a polynucleotide is transcribed into mRNA and translated into a peptide, polypeptide, or protein.

[0071] The term "modulate" includes either a decrease or an increase in activity or expression depending on the target molecule.

[0072] The term "activator" is used herein to denote a molecular species that results in activation of the indicated receptor, whether the species itself binds to the receptor or a metabolite of this species binds to the receptor upon local administration of the species. Thus, the activator may be a ligand of the receptor or an activator that is metabolized to a ligand of the receptor, i.e., a metabolite that is formed in the tissue and is the actual ligand.

[0073] The term "patient" or "mammal" refers to a human, non-human primate, dog, cat, cow, sheep, pig, mouse, or other veterinary or laboratory mammal. One of skill in the art recognizes that a therapeutic agent that reduces the severity of a disease state in one species of mammal is predictive of the effectiveness of that therapeutic agent in another mammalian species.

[0074] The term "soft-drug," as used herein, refers to drugs and / or chemical compounds that are biologically active in a desired target tissue and that are metabolized to compounds that are inactive against the biological target after exerting their effect on the target tissue. In some embodiments, the soft-drug has no target biological activity in the systemic circulation.

[0075] "Pharmaceutically acceptable salt" includes both acid and base addition salts. A pharmaceutically acceptable salt of any one of the compounds described herein is intended to include all pharmaceutically appropriate salt forms. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0076] "Pharmaceutically acceptable acid addition salts" refers to salts which retain the biological effectiveness and properties of the free bases, which salts are not biologically or otherwise undesirable, and are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, etc. Also included are salts formed with organic acids such as aliphatic monocarboxylic acids, aliphatic dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanediol (alkanediol) acids, aromatic acids, aliphatic sulfonic acids, aromatic sulfonic acids, and the like, and which include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Thus, exemplary salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like. Additionally, salts of amino acids such as arginate, gluconate, galacturonate, and the like are contemplated (e.g., Berge SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66:1-19 (1997)). Acid addition salts of basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt.

[0077] "Pharmaceutically acceptable base addition salts" refer to salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared by adding an inorganic or organic base to the free acid. In some embodiments, pharma-ceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals, or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary amines, secondary amines, tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. See Berge et al., supra.

[0078] As used herein, "treatment" or "treating" or "alleviating" or "ameliorating" are used interchangeably herein. These terms refer to an approach to obtain a beneficial or desired result, including but not limited to therapeutic benefit and / or preventive benefit. "Therapeutic benefit" refers to the eradication or reduction of the underlying disease being treated. Moreover, therapeutic benefit is achieved by the eradication or reduction of one or more of the physiological symptoms associated with the underlying disease such that an improvement is observed in the patient, even though the patient still suffers from the underlying disease. In preventive benefit, the composition is administered to a patient at risk of developing a particular disease or who has reported one or more of the physiological symptoms of the disease, even if the particular disease has not been diagnosed.

[0079] TYK2 pseudokinase ligand As a member of the JAK family of tyrosine kinases, TYK2 mediates the signaling of proinflammatory cytokines and therefore represents a target for the treatment of various inflammatory and autoimmune diseases. A striking structural feature of the JAK family is that a pseudokinase (JH2) domain is located immediately N-terminal to the catalytic domain (JH1). Although the JH2 domain shares the overall fold of a typical catalytic domain, the string of individual residues and conformational differences between the TYK2 JH1 and JH2 domains point to the lack of catalytic activity of the JH2 domain. The JH2 domain of the JAK family has been shown to regulate the function of the JH1 domain. The totality of evidence is consistent with the TYK2 pseudokinase domain being autoinhibitory, stabilizing the inactivated state of the kinase domain, and that small molecule ligands can stabilize this autoinhibited conformation in an allosteric manner to prevent protein function.

[0080] The compounds of formula (I') described herein are TYK2 pseudokinase ligands. The compounds of formula (I') described herein, and compositions containing these compounds, are useful for treating inflammatory or autoimmune diseases.

[0081] The urea compounds of formula (I') described herein have better metabolic stability and therefore better in vivo exposure than the corresponding amide compounds. The improved pharmacokinetic properties of the urea compounds compared to the simple amides are due to the proteolytic stability of the urea function. In addition, the substitution of amide with urea changes the nature of the binding interaction with the pseudokinase domain of TYK2, reinforcing the syn anti-urea conformation, which presents both NH and C=O for direct and critical interaction with the rear pocket of the protein. This change in binding form gives rise to different SARs of TYK2 activity and selectivity, as well as improved pharmacokinetic and pharmacological profiles of urea compounds versus amide compounds.

[0082] In some embodiments, provided herein is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof:

[0083] [ka] During the ceremony, X is N or C(R6); Y is C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 aryl, C2-C9 heteroaryl, or

[0084] [ka] and C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, or C2-C9 heteroaryl is optionally substituted by 1, 2, 3, or 4 R7; L1 is a single bond, -O-, -C(O)-, -N(R9)-, -N(R9)CH2-, or -CH2N(R9)-; R1 can be 1, 2, or 3 R 13 is a C3-C6 cycloalkyl substituted with R2, R3, and R4 are independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; R5 is hydrogen or C1-C6 alkyl; each R6 is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; Each R7 is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, C2-C9 heteroaryl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11 , -S(=O)2R 11 , and -S(=O)2N(R 10 )2, selected from C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl and C2-C9 heteroaryl are halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 or two R7 combined to form a 5-, 6-, or 7-membered heterocycloalkyl ring or a 4-, 5-, or 6-membered cycloalkyl ring; R8 is hydrogen, deuterium, halogen, C1-C6 alkyl, or C1-C6 deuteroalkyl; R9 is hydrogen or C1-C6 alkyl; Each R 10 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, and phenyl, where phenyl is selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 Optionally substituted with 1, 2, or 3 groups selected from Each R 11 is independently selected from C1-C6 alkyl and C1-C6 heteroalkyl; Each R 12 is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; Each R 13 are independently selected from halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, C2-C9 heteroaryl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11 , -S(=O)2R 11 , and -S(=O)2N(R 10 )2, selected from C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl and C2-C9 heteroaryl are halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12, -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 Optionally substituted with 1, 2, or 3 groups selected from n is 0, 1, 2, 3, or 4.

[0085] In some embodiments, Y is a C6-C optionally substituted with 1, 2, or 3 R7. 10In some embodiments, the compound of formula (I') is a phenyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is a C2-C9 heteroaryl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is a C2-C9 heteroaryl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') or a pharmaceutically acceptable salt or solvate thereof is selected from the group consisting of oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, optionally substituted by 1, 2, or 3 R7. In some embodiments, the compound of formula (I') or a pharmaceutically acceptable salt or solvate thereof is selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, and -CN. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof is selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt solvate thereof is selected from two R7 combined to form a 5- or 6-membered heterocycloalkyl ring.In some embodiments, the compound of formula (I') or a pharmaceutically acceptable salt solvate thereof is selected from Y, C2-C9 heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl are unsubstituted.

[0086] In some embodiments, the compound of formula (I') is a C2-C9 heterocycloalkyl optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is a C3-C6 cycloalkyl optionally substituted with 1, 2, 3, or 4 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and oxo, or a pharma- ...

[0087] In some embodiments, Y is

[0088] [ka] or a pharma- ceutically acceptable salt or solvate thereof.

[0089] In some embodiments, Y is

[0090] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0091] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0092] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0093] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0094] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0095] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0096] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0097] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0098] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0099] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0100] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0101] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0102] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, Y is

[0103] [ka] or a pharma- ceutically acceptable salt or solvate thereof.

[0104] In some embodiments, the compound of formula (I') is -N(R9)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is -N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is -N(R9)CH2-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is -N(H)CH2-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is -CH2N(R9)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is -CH2N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') is -CH2N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein L1 is a single bond. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein L1 is -O-. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein L1 is -C(O)-.

[0105] In some embodiments, the compound is of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where X is N. In some embodiments, the compound is of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(R6). In some embodiments, the compound is of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(H).

[0106] In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 is hydrogen. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 is C1-C6 alkyl.

[0107] In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R4 is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R4 is hydrogen. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R4 is C1-C6 alkyl.

[0108] In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 is hydrogen and R4 is C1-C6 alkyl. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 and R4 are hydrogen. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 and R4 are C1-C6 alkyl.

[0109] In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is hydrogen. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is C1-C6 alkyl.

[0110] In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R8 is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R8 is hydrogen. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R8 is C1-C6 alkyl.

[0111] In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R5 is hydrogen. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R5 is C1-C6 alkyl.

[0112] In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is hydrogen. In some embodiments, the compound of formula (I') or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is C1-C6 alkyl.

[0113] In some embodiments, R is 1, 2, or 3 R 13 In some embodiments, R is a C3-C6 cycloalkyl optionally substituted with one or two R 13 In some embodiments, R is a C3-C6 cycloalkyl optionally substituted with one R 13 In some embodiments, R is a C3-C6 cycloalkyl optionally substituted with one, two, or three R 13 In some embodiments, R is a cyclopropyl group optionally substituted with one or two R 13In some embodiments, R is a cyclopropyl group optionally substituted with one R 13 In some embodiments, R is a cyclopropyl substituted with one, two, or three R 13 In some embodiments, R is a cyclobutyl optionally substituted with one or two R 13 In some embodiments, R is a cyclobutyl optionally substituted with one R 13 In some embodiments, R is a cyclobutyl substituted with one, two, or three R 13 In some embodiments, R is a cyclopentyl substituted with one, two, or three R 13 In some embodiments, each R is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof. 13 is independently selected from halogen, -OH, -CN, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, and oxo, or a pharma- ceutically acceptable salt or solvate thereof. 13 is independently selected from halogen, -OH, -CN, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 alkoxy, and oxo, or a pharma- ceutically acceptable salt or solvate thereof. 13is independently selected from halogen, -OH, -CN, C1-C6 alkyl, and C1-C6 alkoxy, or a pharma- ceutically acceptable salt or solvate thereof. 13 is independently selected from halogen, -OH, and -CN, or a pharma- ceutically acceptable salt or solvate thereof. 13 is independently selected from halogen. 13 In some embodiments, each R is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof. 13 is -CN, or a pharma- ceutically acceptable salt or solvate thereof.

[0114] In some embodiments, R is 1, 2, or 3 R 13 and each R is a cyclopropyl substituted with 13 is independently selected from halogen, -OH, -CN, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, and oxo, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is selected from one or two R 13 and each R is a cyclopropyl substituted with 13 is independently selected from halogen, -OH, -CN, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 alkoxy, and oxo, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is selected from one R 13 is cyclopropyl substituted by R 13 is selected from halogen, -OH, -CN, C1-C6 alkyl, and C1-C6 alkoxy, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is selected from one R13 is cyclopropyl substituted by R 13 is halogen. In some embodiments, R is one R 13 is cyclopropyl substituted by R 13 In some embodiments, R is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is fluoro. 13 is cyclopropyl substituted by R 13 In some embodiments, R is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is -OH. 13 is cyclopropyl substituted by R 13 In some embodiments, R is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is -CN. 13 is cyclopropyl substituted by R 13 is C1-C6 alkyl. In some embodiments, R1 is one R 13 is cyclopropyl substituted by R 13 is C1-C6 alkoxy. In some embodiments, R1 is one, two, or three R 13 and each R 13 is independently selected from halogen, -OH, -CN, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, and oxo, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is selected from one or two R 13 and each R 13is independently selected from halogen, -OH, -CN, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 alkoxy, and oxo, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is selected from one R 13 is cyclobutyl substituted by R 13 is selected from halogen, -OH, -CN, C1-C6 alkyl, and C1-C6 alkoxy, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is selected from one R 13 is cyclobutyl substituted by R 13 is halogen. In some embodiments, R is one R 13 is cyclobutyl substituted by R 13 In some embodiments, R is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is fluoro. 13 is cyclobutyl substituted by R 13 In some embodiments, R is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is -OH. 13 is cyclobutyl substituted by R 13 In some embodiments, R is a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof, wherein R is -CN. 13 is cyclobutyl substituted by R 13 is C1-C6 alkyl. In some embodiments, R1 is one R 13 is cyclobutyl substituted by R 13 is C1-C6 alkoxy, or a pharma- ceutically acceptable salt or solvate thereof.

[0115] In some embodiments, R1 is

[0116] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is

[0117] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is

[0118] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is

[0119] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is

[0120] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is

[0121] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is

[0122] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is

[0123] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is

[0124] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is

[0125] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is

[0126] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is

[0127] [ka] or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, R1 is

[0128] [ka] or a pharma- ceutically acceptable salt or solvate thereof.

[0129] In some embodiments, provided herein is a compound selected from the following, and pharma- ceutically acceptable salts or solvates thereof:

[0130] [ka]

[0131] [ka]

[0132] In some embodiments, provided herein is a compound selected from the following, or a pharma- ceutically acceptable salt or solvate thereof:

[0133] [ka]

[0134] [ka]

[0135] [ka]

[0136] [ka]

[0137] Any combination of the groups described above in terms of the various variations is contemplated herein. Throughout the specification, groups and substituents thereof may be chosen by one of ordinary skill in the art to provide stable moieties and compounds.

[0138] In some embodiments, the therapeutic agent (e.g., a compound of Formula (I')) is present in the pharmaceutical composition as a pharma- ceutically acceptable salt. In some embodiments, any of the compounds described above are suitable for the methods or compositions described herein.

[0139] The compounds of formula (I), (II), (III), or (IV) described herein are TYK2 pseudokinase ligands. The compounds of formula (I), (II), (III), or (IV) described herein, and compositions containing these compounds, are useful for treating inflammatory or autoimmune diseases.

[0140] The urea compounds of formula (I) or (II) described herein have better metabolic stability and therefore better in vivo exposure than the corresponding amide compounds. The improved pharmacokinetic properties of the urea compounds compared to the simple amides are due to the proteolytic stability of the urea function. In addition, the substitution of amide with urea changes the nature of the binding interaction with the pseudokinase domain of TYK2, reinforcing the syn anti-urea conformation, which presents both NH and C=O for direct and critical interaction with the rear pocket of the protein. Such changes in binding form result in different SARs of TYK2 activity and selectivity, as well as improved pharmacokinetic and pharmacological profiles of urea compounds versus amide compounds.

[0141] In some embodiments, provided herein is a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof:

[0142] [ka] During the ceremony, X is N or C(R6); Y is C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 aryl, C2-C9 heteroaryl, or

[0143] [ka] and C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, or C2-C9 heteroaryl is optionally substituted by 1, 2, 3, or 4 R7; L1 is a single bond, -O-, -C(O)-, -N(R9)-, -N(R9)CH2-, or -CH2N(R9)-; R1 is selected from hydrogen, deuterium, C1-C6 alkyl, C1-C6 deuteroalkyl, C3-C6 cycloalkyl, -C1-C6 alkyl-C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, and C2-C9 heteroaryl, where C1-C6 alkyl, C3-C6 cycloalkyl, -C1-C6 alkyl-C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, or C2-C9 heteroaryl is optionally substituted by 1, 2, or 3 R7; R2, R3, and R4 are independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; R5 is hydrogen or C1-C6 alkyl; each R6 is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; Each R7 is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, C2-C9 heteroaryl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11 , -S(=O)2R 11, and -S(=O)2N(R 10 )2, selected from C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl and C2-C9 heteroaryl are halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 or two R7 combined to form a 5-, 6-, or 7-membered heterocycloalkyl ring or a 4-, 5-, or 6-membered cycloalkyl ring; R8 is hydrogen, deuterium, halogen, C1-C6 alkyl, or C1-C6 deuteroalkyl; R9 is hydrogen or C1-C6 alkyl; Each R 10 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, and phenyl, where phenyl is selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 Optionally substituted with 1, 2, or 3 groups selected from Each R 11 is independently selected from C1-C6 alkyl and C1-C6 heteroalkyl; Each R 12 is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; and n is 0, 1, 2, 3, or 4.

[0144] In some embodiments, Y is a C6-C optionally substituted with 1, 2, or 3 R7. 10In some embodiments, the compound of formula (I) is aryl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I) is phenyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I) is C2-C9 heteroaryl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is selected from the group consisting of oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, optionally substituted by 1, 2, or 3 R7. In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, and -CN. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof is selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt solvate thereof is selected from two R7 combined to form a 5- or 6-membered heterocycloalkyl ring.In some embodiments, Y is a C2-C9 heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl are unsubstituted, or a pharma- ceutically acceptable salt solvate thereof.

[0145] In some embodiments, the compound of formula (I) is a C2-C9 heterocycloalkyl optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I) is a C3-C6 cycloalkyl optionally substituted with 1, 2, 3, or 4 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (I) is a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and oxo ...

[0146] In some embodiments, Y is

[0147] [ka] or a pharma- ceutically acceptable salt or solvate thereof.

[0148] In some embodiments, L1 is a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, L1 is a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, L1 is a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, L1 is a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, L1 is a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, L1 is a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, L1 is a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, L1 is a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, L1 is a compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, L1 is a single bond. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein L1 is -O-. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein L1 is -C(O)-.

[0149] In some embodiments, the compound is of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where X is N. In some embodiments, the compound is of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(R6). In some embodiments, the compound is of formula (I), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(H).

[0150] In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 is hydrogen. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 is C1-C6 alkyl.

[0151] In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof is selected from hydrogen and C1-C6 alkyl. ...

[0152] In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 is hydrogen and R4 is C1-C6 alkyl. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 and R4 are hydrogen. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 and R4 are C1-C6 alkyl.

[0153] In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is hydrogen. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is C1-C6 alkyl.

[0154] In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof is selected from hydrogen and C1-C6 alkyl. ...

[0155] In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R5 is hydrogen. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R5 is C1-C6 alkyl.

[0156] In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is hydrogen. In some embodiments, the compound of formula (I) or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is C1-C6 alkyl.

[0157] In some embodiments, the compound is of formula (I), where R1 is hydrogen, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (I), where R1 is C1-C6 alkyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (I), where R1 is unsubstituted C1-C6 alkyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (I), where R1 is C1-C6 deuteroalkyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (I), where R1 is C3-C6 cycloalkyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (I), where R1 is unsubstituted C3-C6 cycloalkyl, or a pharma- ceutically acceptable salt or solvate thereof.

[0158] In some embodiments, provided herein is a compound of formula (II), or a pharma- ceutically acceptable salt or solvate thereof:

[0159] [ka] During the ceremony, X is N or C(R6); Y is C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 aryl, C2-C9 heteroaryl, or

[0160] [ka] and C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, or C2-C9 heteroaryl is optionally substituted by 1, 2, 3, or 4 R7; L1 is a single bond, -O-, -C(O)-, -N(R9)-, -N(R9)CH2-, or -CH2N(R9)-; R1 is selected from hydrogen, deuterium, C1-C6 alkyl, C1-C6 deuteroalkyl, C3-C6 cycloalkyl, -C1-C6 alkyl-C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, and C2-C9 heteroaryl, where C1-C6 alkyl, C3-C6 cycloalkyl, -C1-C6 alkyl-C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, or C2-C9 heteroaryl is optionally substituted by 1, 2, or 3 R7; R2, R3, and R4 are independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; R5 is hydrogen or C1-C6 alkyl; each R6 is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; Each R7 is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, C2-C9 heteroaryl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11 , -S(=O)2R 11 , and -S(=O)2N(R 10 )2, selected from C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl and C2-C9 heteroaryl are halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 or two R7 combined to form a 5-, 6-, or 7-membered heterocycloalkyl ring or a 4-, 5-, or 6-membered cycloalkyl ring; R8 is hydrogen, deuterium, halogen, C1-C6 alkyl, or C1-C6 deuteroalkyl; R9 is hydrogen or C1-C6 alkyl; Each R 10 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, and phenyl, where phenyl is selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 Optionally substituted with 1, 2, or 3 groups selected from Each R 11 is independently selected from C1-C6 alkyl and C1-C6 heteroalkyl; Each R 12 is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; and n is 0, 1, 2, 3, or 4.

[0161] In some embodiments, Y is a C6-C optionally substituted with 1, 2, or 3 R7. 10In some embodiments, the compound of formula (II) is aryl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is phenyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is C2-C9 heteroaryl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof is selected from the group consisting of oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, optionally substituted by 1, 2, or 3 R7. In some embodiments, the compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof is selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, and -CN. In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof is selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt solvate thereof is selected from two R7 combined to form a 5- or 6-membered heterocycloalkyl ring.In some embodiments, the compound of formula (II) or a pharmaceutically acceptable salt solvate thereof is selected from Y, C2-C9 heteroaryl selected from oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl are unsubstituted.

[0162] In some embodiments, the compound of formula (II) is a C2-C9 heterocycloalkyl optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is a C3-C6 cycloalkyl optionally substituted with 1, 2, 3, or 4 R7, or a pharma-ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and oxo ...

[0163] In some embodiments, Y is

[0164] [ka] or a pharma- ceutically acceptable salt or solvate thereof.

[0165] In some embodiments, the compound of formula (II) is -N(R9)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is -N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is -N(R9)CH2-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is -N(H)CH2-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is -CH2N(R9)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is -CH2N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is -CH2N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is -CH2N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is -A ... In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof, wherein L1 is -O-. In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof, wherein L1 is -C(O)-.

[0166] In some embodiments, the compound is of formula (II), or a pharma- ceutically acceptable salt or solvate thereof, where X is N. In some embodiments, the compound is of formula (II), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(R6). In some embodiments, the compound is of formula (II), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(H).

[0167] In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof is selected from hydrogen and C1-C6 alkyl. ...

[0168] In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof is selected from hydrogen and C1-C6 alkyl. ...

[0169] In some embodiments, the compound is of formula (II), or a pharma- ceutically acceptable salt or solvate thereof, where R3 is hydrogen and R4 is C1-C6 alkyl. In some embodiments, the compound is of formula (II), or a pharma- ceutically acceptable salt or solvate thereof, where R3 and R4 are hydrogen. In some embodiments, the compound is of formula (II), or a pharma- ceutically acceptable salt or solvate thereof, where R3 and R4 are C1-C6 alkyl.

[0170] In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is hydrogen. In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is C1-C6 alkyl.

[0171] In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof is selected from hydrogen and C1-C6 alkyl. ...

[0172] In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof, wherein R5 is hydrogen. In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof, wherein R5 is C1-C6 alkyl.

[0173] In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is hydrogen. In some embodiments, the compound of formula (II) or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is C1-C6 alkyl.

[0174] In some embodiments, the compound is of formula (II), where R1 is hydrogen, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (II), where R1 is C1-C6 alkyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (II), where R1 is unsubstituted C1-C6 alkyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (II), where R1 is C1-C6 deuteroalkyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (II), where R1 is C3-C6 cycloalkyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (II), where R1 is unsubstituted C3-C6 cycloalkyl, or a pharma- ceutically acceptable salt or solvate thereof.

[0175] In some embodiments, provided herein is a compound of formula (III), or a pharma- ceutically acceptable salt or solvate thereof:

[0176] [ka] During the ceremony, X is N or C(R6); Y is C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, or C2-C9 heteroaryl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, or C2-C9 heteroaryl is optionally substituted with 1, 2, 3, or 4 R7; L1 is a single bond, -O-, -C(O)-, -N(R9)-, -N(R9)CH2-, or -CH2N(R9)-; L2 is a single bond, -N(R9)-, -O-, C1-C6 alkyl, or C3-C6 cycloalkyl; Each R1 is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11 , -S(=O)2R 11 , and -S(=O)2N(R 10 or two R1 combined to form a 3-, 4-, 5-, or 6-membered cycloalkyl ring or a 3-, 4-, 5-, or 6-membered heterocycloalkyl ring; R2, R3, and R4 are independently selected from hydrogen, deuterium, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, and C2-C9 heterocycloalkyl; R5 is hydrogen or C1-C6 alkyl; each R6 is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; Each R7 is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, C2-C9 heteroaryl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11 , -S(=O)2R11 , and -S(=O)2N(R 10 )2, selected from C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl and C2-C9 heteroaryl are halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 or two R7 combined to form a 5-, 6-, or 7-membered heterocycloalkyl ring or a 4-, 5-, or 6-membered cycloalkyl ring; R8 is hydrogen, deuterium, halogen, C1-C6 alkyl, or C1-C6 deuteroalkyl; R9 is hydrogen or C1-C6 alkyl; Each R 10 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, and phenyl, where phenyl is selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 Optionally substituted with 1, 2, or 3 groups selected from Each R 11 is independently selected from C1-C6 alkyl and C1-C6 heteroalkyl; Each R 12 is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; and p is 0, 1, 2, 3, or 4.

[0177] In some embodiments, Y is a C6-C optionally substituted with 1, 2, or 3 R7. 10 In some embodiments, the compound of formula (III) is aryl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is phenyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is unsubstituted phenyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is C2-C9 heteroaryl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof is selected from the group consisting of oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, optionally substituted by 1, 2, or 3 R7. In some embodiments, the compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof is selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, and -CN. In some embodiments, the compound of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, is a compound of formula (III), wherein Y is a C2-C9 heteroaryl selected from the following:

[0178] [ka]

[0179] In some embodiments, the compound of formula (III) is a C2-C9 heterocycloalkyl optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is a C3-C6 cycloalkyl optionally substituted with 1, 2, 3, or 4 R7, or a pharma-ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (II) is a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, and oxo, or a pharma-ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is a C2-C9 heterocycloalkyl selected from the following:

[0180] [ka]

[0181] In some embodiments, the compound of formula (III) is -N(R9)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is -N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is -N(R9)CH2-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is -N(H)CH2-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is -CH2N(R9)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is -CH2N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is -CH2N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is -CH2N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is -A ... In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein L1 is -O-. In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein L1 is -C(O)-.

[0182] In some embodiments, the compound of formula (III) is -N(R9)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is -N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is -O-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is -C1-C6 alkyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (III) is -C3-C6 cycloalkyl, or a pharma- ceutically acceptable salt or solvate thereof.

[0183] In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, where X is N. In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(R6). In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(H).

[0184] In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 is hydrogen. In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 is C1-C6 alkyl.

[0185] In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R4 is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R4 is hydrogen. In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R4 is C1-C6 alkyl.

[0186] In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, where R3 is hydrogen and R4 is C1-C6 alkyl. In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, where R3 and R4 are hydrogen. In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, where R3 and R4 are C1-C6 alkyl.

[0187] In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is hydrogen. In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is C1-C6 alkyl.

[0188] In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof is selected from hydrogen and C1-C6 alkyl. ...

[0189] In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R5 is hydrogen. In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R5 is C1-C6 alkyl.

[0190] In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is hydrogen. In some embodiments, the compound of formula (III) or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is C1-C6 alkyl.

[0191] In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, in which each R is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, in which each R is hydrogen. In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, in which two R combine to form a 3-, 4-, 5-, or 6-membered cycloalkyl ring, or a 3-, 4-, 5-, or 6-membered heterocycloalkyl ring. In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, in which p is 0. In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, in which p is 1. In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, in which p is 2. In some embodiments, the compound is of formula (III), or a pharma- ceutically acceptable salt or solvate thereof, in which p is 3.

[0192] In some embodiments, provided herein is a compound of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof:

[0193] [ka] During the ceremony, X is N or C(R6); Y is C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, or C2-C9 heteroaryl, wherein the C1-C6 alkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, or C2-C9 heteroaryl is optionally substituted with 1, 2, 3, or 4 R7; L1 is a single bond, -O-, -C(O)-, -N(R9)-, -N(R9)CH2-, or -CH2N(R9)-; L2 is a single bond, -N(R9)-, -O-, C1-C6 alkyl, or C3-C6 cycloalkyl; Each R1 is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11 , -S(=O)2R 11 , and -S(=O)2N(R 10 or two R1 combined to form a 3-, 4-, 5-, or 6-membered cycloalkyl ring or a 3-, 4-, 5-, or 6-membered heterocycloalkyl ring; R2, R3, and R4 are independently selected from hydrogen, deuterium, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, and C2-C9 heterocycloalkyl; R5 is hydrogen or C1-C6 alkyl; each R6 is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 deuteroalkyl; Each R7 is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 deuteroalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl, C2-C9 heteroaryl, oxo, -OR 10 , -N(R 10 )2, -CN, -C(=O)R 11 , -C(=O)OR 10 , -C(=O)N(R 10 )2, -NR 10 C(=O)R 11 , -NR 10 S(=O)2R 11, -S(=O)2R 11 , and -S(=O)2N(R 10 )2, selected from C3-C6 cycloalkyl, C2-C9 heterocycloalkyl, C6-C 10 Aryl and C2-C9 heteroaryl are halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 or two R7 combined to form a 5-, 6-, or 7-membered heterocycloalkyl ring or a 4-, 5-, or 6-membered cycloalkyl ring; R8 is hydrogen, deuterium, halogen, C1-C6 alkyl, or C1-C6 deuteroalkyl; R9 is hydrogen or C1-C6 alkyl; Each R 10 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, and phenyl, where phenyl is selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C9 heterocycloalkyl, C2-C9 heteroaryl, -OR 12 , -N(R 12 )2, -C(=O)OR 12 , and -C(=O)N(R 12 Optionally substituted with 1, 2, or 3 groups selected from Each R 11 is independently selected from C1-C6 alkyl and C1-C6 heteroalkyl; Each R 12 is independently selected from hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl; and p is 0, 1, 2, 3, or 4.

[0194] In some embodiments, Y is a C6-C optionally substituted with 1, 2, or 3 R7. 10 In some embodiments, the compound of formula (IV) is a phenyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IV) is a phenyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IV) is a phenyl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IV) is a C2-C9 heteroaryl, optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IV) or a pharmaceutically acceptable salt or solvate thereof is selected from the group consisting of oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein oxazolyl, thiazolyl, pyrazolyl, furanyl, thienyl, pyrrolyl, imidazolyl, triazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, optionally substituted by 1, 2, or 3 R7. In some embodiments, the compound of formula (IV) or a pharmaceutically acceptable salt or solvate thereof is selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, and -CN. In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, wherein Y is a C2-C9 heteroaryl selected from the following:

[0195] [ka]

[0196] In some embodiments, the compound of formula (IV) is a C2-C9 heterocycloalkyl optionally substituted with 1, 2, or 3 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IV) is a C3-C6 cycloalkyl optionally substituted with 1, 2, 3, or 4 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IV) is a C2-C9 heterocycloalkyl optionally substituted with 1, 2, 3, or 4 R7, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IV) is a C2-C9 heterocycloalkyl selected from the following, or a pharma- ceutically acceptable salt or solvate thereof.

[0197] [ka]

[0198] In some embodiments, the compound is of formula (IV), where L1 is -N(R9)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (IV), where L1 is -N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (IV), where L1 is -N(R9)CH2-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (IV), where L1 is -N(H)CH2-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (IV), where L1 is -CH2N(R9)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (IV), where L1 is -CH2N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound is of formula (IV), where L1 is a single bond, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IV) or a pharma- ceutically acceptable salt or solvate thereof, wherein L1 is -O-. In some embodiments, the compound of formula (IV) or a pharma- ceutically acceptable salt or solvate thereof, wherein L1 is -C(O)-.

[0199] In some embodiments, the compound of formula (IV) is -N(R9)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IV) is -N(H)-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IV) is -O-, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IV) is -C1-C6 alkyl, or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IV) is -C3-C6 cycloalkyl, or a pharma- ceutically acceptable salt or solvate thereof.

[0200] In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, where X is N. In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(R6). In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, where X is C(H).

[0201] In some embodiments, the compound of formula (IV) or a pharma- ceutically acceptable salt or solvate thereof is selected from hydrogen and C1-C6 alkyl. ...

[0202] In some embodiments, the compound of formula (IV) or a pharma- ceutically acceptable salt or solvate thereof is selected from hydrogen and C1-C6 alkyl. ...

[0203] In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, where R3 is hydrogen and R4 is C1-C6 alkyl. In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, where R3 and R4 are hydrogen. In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, where R3 and R4 are C1-C6 alkyl.

[0204] In some embodiments, the compound of formula (IV) or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound of formula (IV) or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is hydrogen. In some embodiments, the compound of formula (IV) or a pharma- ceutically acceptable salt or solvate thereof, wherein R6 is C1-C6 alkyl.

[0205] In some embodiments, the compound of formula (IV) or a pharma- ceutically acceptable salt or solvate thereof is selected from hydrogen and C1-C6 alkyl. ...

[0206] In some embodiments, the compound of formula (IV) or a pharma- ceutically acceptable salt or solvate thereof, wherein R5 is hydrogen. In some embodiments, the compound of formula (IV) or a pharma- ceutically acceptable salt or solvate thereof, wherein R5 is C1-C6 alkyl.

[0207] In some embodiments, the compound of formula (IV) or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is hydrogen. In some embodiments, the compound of formula (IV) or a pharma- ceutically acceptable salt or solvate thereof, wherein R2 is C1-C6 alkyl.

[0208] In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which each R is selected from hydrogen and C1-C6 alkyl. In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which each R is hydrogen. In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which two R combine to form a 3-, 4-, 5-, or 6-membered cycloalkyl ring, or a 3-, 4-, 5-, or 6-membered heterocycloalkyl ring. In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which p is 0. In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which p is 1. In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which p is 2. In some embodiments, the compound is of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof, in which p is 3.

[0209] In some embodiments, provided herein is a compound selected from the following, or a pharma- ceutically acceptable salt or solvate thereof:

[0210] [ka]

[0211] [ka]

[0212] In some embodiments, provided herein is a compound selected from the following, or a pharma- ceutically acceptable salt or solvate thereof:

[0213] [ka]

[0214] Any combination of the groups described above in terms of the various variations is contemplated herein. Throughout the specification, groups and substituents thereof may be chosen by one of ordinary skill in the art to provide stable moieties and compounds.

[0215] In some embodiments, the therapeutic agent (e.g., a compound of Formula (I), (II), (III), or (IV)) is present in the pharmaceutical composition as a pharma- ceutically acceptable salt. In some embodiments, any of the compounds described above are suitable for the methods or compositions described herein.

[0216] Further forms of the compounds disclosed herein Isomers Further, in some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds described herein include cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers, as well as all of the corresponding mixtures thereof. In some circumstances, the compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. In some circumstances, the compounds described herein have one or more chiral centers, with each center being in the R or S configuration. The compounds described herein include diastereomeric, enantiomeric, and epimeric forms, as well as all of the corresponding mixtures thereof. In further embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereoisomers obtained from a single preparation step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as optically pure enantiomers by chiral chromatographic separation of a racemic mixture. In some embodiments, the compounds described herein are prepared as individual stereoisomers of the compound by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomers. In some embodiments, dissociable complexes are preferred (e.g., crystalline diastereomeric salts). In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubility, reactivity, etc.) and are separated by taking advantage of these differences. In some embodiments, the diastereomers are separated by chiral chromatography, or preferably by separation / resolution techniques based on differences in solubility. In some embodiments, the optically pure enantiomers are subsequently recovered along with the resolving agent by any practical means that does not result in racemization.

[0217] labeled compound In some embodiments, the compounds described herein are present in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods of treating disease by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods of treating disease by administering such isotopically labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically labeled compounds that are identical to those listed herein except for the fact that one or more atoms are replaced with an atom having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Examples of isotopes that may be incorporated into the compounds described herein include: 2 H, 3 H, 13 C. 14 C. 15 N, 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 The isotopes include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chloride, such as Cl. Compounds described herein that contain the aforementioned isotopes and / or other isotopes of other atoms, as well as pharma- ceutically acceptable salts, esters, solvates, hydrates, or derivatives thereof, are within the scope of the present invention. Certain isotopically labeled compounds, e.g. 3 H and 14 Compounds incorporating a radioactive isotope, such as C, are useful in drug and / or substrate tissue distribution assays. Tritiated, i.e. 3 H and carbon 14, i.e. 14 C isotopes are particularly preferred for their ease of preparation and detectability. Additionally, deuterium, i.e. 2Substitution with heavy isotopes, such as H, offers certain therapeutic advantages resulting from greater metabolic stability, e.g., increased half-life in vivo or reduced dosage requirements. In some embodiments, isotopically labeled compounds, pharma- ceutically acceptable salts, esters, solvates, hydrates, or derivatives thereof are prepared by any suitable method.

[0218] In some embodiments, the compounds described herein are labeled by other means, including but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, chemiluminescent labels.

[0219] Pharmaceutically acceptable salts In some embodiments, the compounds described herein are present as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.

[0220] In some embodiments, the compounds described herein contain acidic or basic groups and can be reacted with any of a number of inorganic or organic bases, inorganic or organic acids to produce pharma- ceutically acceptable salts. In some embodiments, these salts are prepared during the final isolation and purification of the compounds described herein, or in situ by separately reacting the purified compounds in free form with the appropriate acid or base and isolating the resulting salt.

[0221] solvate In some embodiments, the compounds described herein exist as solvates. In some embodiments, methods of treating diseases by administering the solvates. Further described herein are methods of treating diseases by administering such solvates as pharmaceutical compositions.

[0222] Solvates contain stoichiometric or non-stoichiometric amounts of solvent, and in some embodiments are formed during the crystallization process using pharma- ceutically acceptable solvents such as water or ethanol. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein are conveniently prepared or formed during the processes described herein. By way of example only, hydrates of the compounds described herein are conveniently prepared by recrystallization from aqueous / organic solvent mixtures using organic solvents including, but not limited to, dioxane, tetrahydrofuran, MeOH. In addition, the compounds provided herein exist in unsolvated as well as solvated forms. Generally, solvated forms are considered equivalent to unsolvated forms for the purposes of the compounds and methods provided herein.

[0223] Compound synthesis In some embodiments, synthesis of the compounds described herein is accomplished using means described in the chemical literature, using methods described herein, or a combination thereof. Additionally, solvents, temperatures, and other reaction conditions presented herein may be varied.

[0224] In other embodiments, the starting materials and reagents used in the synthesis of the compounds described herein are synthesized or obtained from commercial sources, including, but not limited to, Sigma-Aldrich, Fischer Scientific (Fischer Chemicals), and AcrosOrganics.

[0225] In further embodiments, the compounds described herein, and other related compounds having various substituents, can be prepared by any method, including, but not limited to, the techniques and materials described herein, as well as by any method, including ... Ed., (Wiley 1999) (all of which are incorporated by reference for disclosure). General methods for the preparation of compounds as disclosed herein may be derived from reactions that can be modified using appropriate reagents and conditions to introduce the various moieties found in the formulas provided herein. The following synthetic methods may be used as a guide.

[0226] Use of Protecting Groups In the reactions described, it may be necessary to protect reactive functional groups, such as hydroxy, amino, imino, thio, or carboxy groups, to prevent them from participating in the reaction in an unwanted manner if desired in the final product. Protecting groups are used to block some or all of the reactive moieties and prevent such groups from participating in chemical reactions until the protecting group is removed. Each protecting group is preferably removable by a different means. Protecting groups that are cleaved under generally different reaction conditions fulfill the requirement of differential removal.

[0227] The protecting groups can be removed by acid, base, reducing conditions (e.g., hydrogenolysis), and / or oxidative conditions. Groups such as trityl, dimethoxytrityl, acetal, t-butyldimethylsilyl, etc., may be used to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected with Cbz groups, which are acidolytic and hydrogenolytically removable, and Fmoc groups, which are base labile. Carboxylic acid and hydroxy reactive moieties may be blocked with base labile groups, such as, but not limited to, methyl, ethyl, acetyl, etc., in the presence of amines blocked with acid labile groups, such as t-butyl carbamate, or with carbamates, which are acid and base stable, but hydrolytically removable.

[0228] Carboxylic acid and hydroxy reactive sites may further be blocked with hydrolytically removable protecting groups such as benzyl groups, while amine groups capable of hydrogen bonding with acids may be blocked with base-labile groups such as Fmoc. Carboxylic acid reactive sites may be protected by conversion to simple ester compounds as exemplified herein, including conversion to alkyl esters, or may be blocked with oxidatively removable protecting groups such as 2,4-dimethoxybenzyl, while coexisting amino groups may be blocked with fluoride-labile silyl carbamates.

[0229] Allyl blocking groups are useful in the presence of acid and base protecting groups because the acid blocking groups are stable and can be subsequently removed by metal or pi-acid catalysts. For example, allyl-blocked carboxylic acids can be reacted with Pd 0 -Can be deprotected by catalytic reactions. Another form of protecting group is a resin to which a compound or intermediate may be attached. As long as the residue is attached to the resin, its functional group is blocked and cannot react. Once released from the resin, the functional group becomes available for reaction.

[0230] In general, blocking / protecting groups may be selected from:

[0231] [ka]

[0232] Details of other protecting groups, as well as applicable techniques for the creation and removal of protecting groups, are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference for their disclosure.

[0233] Treatment and prevention methods In some embodiments, a method of treating an inflammatory disease or an autoimmune disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, a method of treating an inflammatory disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, a method of treating an autoimmune disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, a method of treating an inflammatory or autoimmune disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease, disorder, or condition is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, lupus, bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, vitiligo, and atopic dermatitis. In some embodiments, a method of treating an inflammatory or autoimmune disease in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease, disorder, or condition is rheumatoid arthritis. In some embodiments, a method of treating an inflammatory or autoimmune disease in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease, disorder, or condition is multiple sclerosis.In some embodiments, a method of treating an inflammatory disease or autoimmune disease in a patient comprises administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, and the disease, disorder, or condition is psoriasis. In some embodiments, a method of treating an inflammatory disease or autoimmune disease in a patient comprises administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, and the disease, disorder, or condition is lupus. In some embodiments, a method of treating an inflammatory disease or autoimmune disease in a patient comprises administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, and the disease, disorder, or condition is a bowel disease. In some embodiments, a method of treating an inflammatory or autoimmune disease in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease, disorder, or condition is Crohn's disease. In some embodiments, a method of treating an inflammatory or autoimmune disease in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease, disorder, or condition is ulcerative colitis. In some embodiments, a method of treating an inflammatory or autoimmune disease in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease, disorder, or condition is ankylosing spondylitis.In some embodiments, a method of treating an inflammatory or autoimmune disease in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease, disorder, or condition is vitiligo. In some embodiments, a method of treating an inflammatory or autoimmune disease in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof, wherein the disease, disorder, or condition is atopic dermatitis.

[0234] Pharmaceutical Compositions and Methods of Administration The TYK2 pseudokinase ligands described herein are administered to a subject in a biologically compatible form suitable for local administration to treat or prevent a disease, disorder, or condition. Administration of the TYK2 pseudokinase ligand as described herein may be in a pharmacological form that includes a therapeutically effective amount of the TYK2 pseudokinase ligand alone or in combination with a pharma- ceutically acceptable carrier.

[0235] In some embodiments, the compounds described herein are administered as pure chemicals. In other embodiments, the compounds described herein are combined with a pharma- ceutically suitable or acceptable carrier (also referred to herein as a pharma- ceutically suitable (or acceptable) excipient, a physiologically suitable (or acceptable) excipient, or a physiologically suitable (or acceptable) carrier) selected based on the selected route of administration and standard pharmaceutical practice, e.g., as described in Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)).

[0236] Thus, provided herein are pharmaceutical compositions comprising at least one compound as described herein, or a pharma- ceutically acceptable salt thereof, together with one or more pharma- ceutically acceptable carriers. A carrier (or excipient) is acceptable or suitable if it is compatible with the other ingredients of the composition and not deleterious to the recipient (subject) of the composition.

[0237] In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of formula (II), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of formula (III), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, there is a pharmaceutical composition comprising a pharma- ceutically acceptable carrier and a compound of formula (IV), or a pharma- ceutically acceptable salt or solvate thereof.

[0238] Another embodiment provides a pharmaceutical composition consisting essentially of a pharma- ceutically acceptable carrier and a compound of formula (I'), (I), (II), (III), or (IV), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition consists essentially of a pharma- ceutically acceptable carrier and a compound of formula (I'), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition consists essentially of a pharma- ceutically acceptable carrier and a compound of formula (I), or a pharma- ceutically acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition consists essentially of a pharma- ceutically acceptable carrier and a compound of formula (II), or a pharma- ceutical acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition consists essentially of a pharma- ceutical acceptable carrier and a compound of formula (III), or a pharma- ceutical acceptable salt or solvate thereof. In some embodiments, the pharmaceutical composition consists essentially of a pharma- ceutical acceptable carrier and a compound of formula (IV), or a pharma- ceutical acceptable salt or solvate thereof.

[0239] In certain embodiments, the compounds described herein are substantially pure in that they contain less than about 5%, less than about 1%, or less than about 0.1% of other small organic molecules, such as contaminating intermediates or by-products that may arise during, for example, one or more of the steps of a synthetic method.

[0240] These formulations include those suitable for oral, topical, buccal, parenteral (eg, subcutaneous, intramuscular, intradermal, or intravenous) or aerosol administration.

[0241] Typical pharmaceutical compositions are used in the form of pharmaceutical preparations, such as solid, semi-solid, or liquid forms, which contain one or more of the disclosed compounds as active ingredients mixed with organic or inorganic carriers or excipients suitable for in vitro, enteral, or parenteral use. In some embodiments, the active ingredient is usually formulated with a non-toxic, pharma- ceutically acceptable carrier, such as tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and other forms suitable for use. The active subject compound is included in the pharmaceutical composition in an amount sufficient to exert the desired effect on the process or condition of the disease.

[0242] In some embodiments, the TYK2 pseudokinase ligands described herein are administered to a subject in a biologically compatible form suitable for topical administration to treat or prevent a skin disease, disorder, or condition. "Biologically compatible form suitable for topical administration" refers to a form of the TYK2 pseudokinase ligand administered in which any toxic effects outweigh the therapeutic benefits of the inhibitor. Administration of the TYK2 pseudokinase ligand as described herein may be in a pharmacological form that includes a therapeutically effective amount of the TYK2 pseudokinase ligand alone or in combination with a pharma- ceutical acceptable carrier.

[0243] The topical administration of TYK2 pseudokinase inhibitors can be provided in the form of an aerosol, semi-solid pharmaceutical composition, powder, or solution. The term "semi-solid composition" refers to an ointment, cream, salve, jelly, or other pharmaceutical composition with substantially similar consistency suitable for application to the skin. Examples of semi-solid compositions are provided in Chapter 17 of The Theory and Practice of Industrial Pharmacy, Lachman, Lieberman and Kanig, published by Lea and Febiger (1970), and Chapter 67 of Remington's Pharmaceutical Sciences, 15th Edition, published by Mack Publishing Company (1975).

[0244] Dermal or skin patches are another method of transdermal delivery of the therapeutic or pharmaceutical compositions described herein. Patches can provide an absorption enhancer, such as DMSO, to increase absorption of the compound. Patches may include those that control the rate of drug delivery to the skin. Patches may provide various administration systems, including reservoir systems or monolithic systems, respectively. Reservoir designs may have, for example, four layers: an adhesive layer that directly contacts the skin, a control membrane that controls the diffusion of the drug molecules, a reservoir of drug molecules, and a water-resistant backing. Such designs deliver a uniform amount of drug over a specific period of time, and the delivery rate must be below the saturation limit of various skin types. Monolithic designs, for example, typically have only three layers: an adhesive layer, a polymer matrix that contains the compound, and a water-impermeable backing. This design provides a saturating amount of drug to the skin. Delivery is thereby controlled by the skin. When the amount of drug falls below the saturation amount in the patch, the delivery rate decreases.

[0245] In one embodiment, the topical composition may be in the form of a hydrogel, for example based on polyacrylic acid or polyacrylamide, in the form of an ointment containing polyethylene glycol (PEG) as a carrier, for example the standard ointment DAB8 (50% PEG300, 50% PEG1500), or in the form of an emulsion, in particular a microemulsion based on water-in-oil or oil-in-water, optionally with the addition of liposomes. Suitable penetration enhancers (entraining agents) include sulfoxide derivatives such as dimethyl sulfoxide (DMSO) or decyl methyl sulfoxide (decyl-MSO), and transcutol (diethylene glycol monoethyl ether) or cyclodextrins, as well as pyrrolidones, such as 2-pyrrolidone, N-methyl-2-pyrrolidone, 2-pyrrolidone-5-carboxylic acid, or biodegradable N-(2-hydroxyethyl)-2-pyrrolidone, and their fatty acid esters; urea derivatives, such as dodecyl urea, 1,3-didodecyl urea, 1,3-diphenyl urea; terpenes, such as D-limonene, menthone, a-terpinol, carbol, limonene oxide, 1,8-cineole.

[0246] Ointments, pastes, creams, and gels may further contain excipients such as starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicic acid, talc, or mixtures thereof. Powders and sprays may further contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures of these substances. The solution of nanocrystalline antimicrobial metals can be converted into an aerosol or spray by any of the known means routinely used to make aerosol formulations. Typically, such methods include pressurizing a container of the solution with, or providing a means for pressurization, a carrier gas, usually inert, and passing the pressurized gas through a small orifice. In addition, sprays may contain conventional propellants such as chlorofluorohydrocarbons, and volatile unsubstituted hydrocarbons such as butane and propane.

[0247] The carrier may further include other pharma- ceutically acceptable excipients to modify or maintain the pH, osmolarity, viscosity, clarity, color, sterility, stability, dissolution rate, or odor of the formulation. The anti-skin aging composition may further include antioxidants, sunscreens, natural retinoids (e.g., retinol), and other additives commonly found in skin treatment compositions.

[0248] In some embodiments for preparing solid compositions such as tablets, the primary active ingredient is mixed with a pharmaceutical carrier, e.g., conventional tablet ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogenous mixture of the disclosed compound or a non-toxic, pharma-ceutically acceptable salt thereof. When such a preformulation composition is referred to as homogenous, it is meant that the active ingredient is evenly dispersed throughout the composition such that the composition may be readily subdivided into equally effective unit dosage forms, such as tablets, pills, capsules, and the like.

[0249] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, etc.), the subject compositions may be formulated with one or more pharma- ceutically acceptable carriers, such as sodium citrate and dicalcium phosphate, and / or (1) fillers or extenders, such as starch, cellulose, microcrystalline cellulose, silicided microcrystalline cellulose, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) saccharides, such as carboxymethylcellulose, hypromellose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia. (3) a diluent such as glycerin, (4) a disintegrating agent such as crospovidone, croscarmellose sodium, sodium starch glycolate, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (5) a solution retardant such as paraffin, (6) an absorption promoter such as a quaternary ammonium compound, (7) a wetting agent such as docusate sodium, cetyl alcohol, glycerol monostearate, (8) an absorbent such as kaolin or bentonite clay, (9) a lubricant such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, mixtures thereof, and (10) a coloring agent. In the case of capsules, tablets, and pills, in some embodiments, the composition comprises a buffering agent. In some embodiments, solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar, as well as high molecular weight polyethylene glycols and the like.

[0250] In some embodiments, tablets are made by compression or molding, optionally with one or more accessory ingredients. In some embodiments, compressed tablets are prepared using binders (e.g., gelatin, hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate, cross-linked sodium carboxymethylcellulose), surface active agents, or dispersants. In some embodiments, molded tablets are made by molding a mixture of the subject composition moistened with an inert liquid diluent in a suitable machine. In some embodiments, tablets and other solid dosage forms, such as dragees, capsules, pills, and granules, are scored or prepared with coatings and shells, such as enteric coatings and other coatings.

[0251] Compositions for inhalation or insufflation include solutions and suspensions in pharma- ceutically acceptable aqueous or organic solvents, or mixtures thereof, and powders.Liquid dosage forms for oral administration include pharma-ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.In addition to the subject compositions, in some embodiments, liquid dosage forms contain inert diluents such as water or other solvents, solubilizers, emulsifiers, for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol, fatty acid esters of sorbitan, cyclodextrin, and mixtures thereof.

[0252] In some embodiments, the suspension contains, in addition to the subject composition, a suspending agent such as, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol, sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, tragacanth, and mixtures thereof.

[0253] In some embodiments, powders and sprays contain, in addition to the subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures of these substances. In some embodiments, sprays further contain conventional propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0254] The compositions and compounds disclosed herein are alternatively administered by aerosol. This is accomplished by preparing an aerosol aqueous solution, liposomal preparation, or solid particles containing the compound. In some embodiments, a non-aqueous (e.g., fluorocarbon propellant) suspension is used. In some embodiments, a sonic nebulizer is used, which results in the decomposition of the compound contained in the subject composition. This is because it minimizes the shearing of the drug. Typically, an aqueous aerosol solution is made by formulating an aqueous solution or suspension of the subject composition together with conventional pharma- ceutically acceptable carriers and stabilizers. Carriers and stabilizers vary depending on the requirements of the particular subject composition, but typically include non-ionic surfactants (Tween, Pluronic, polyethylene glycol), non-toxic proteins such as serum albumin, sorbitan esters, amino acids such as oleic acid, lecithin, glycine, buffers, salts, sugars, or sugar alcohols. Aerosols are typically prepared from isotonic solutions.

[0255] Pharmaceutical compositions suitable for parenteral administration may comprise the subject composition in combination with one or more pharma- ceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions, or sterile powders to be reconstituted into injectable sterile solutions or dispersions immediately prior to use, which in some embodiments contain antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient, suspending agents, or thickening agents.

[0256] Examples of suitable aqueous and non-aqueous carriers that can be used in pharmaceutical compositions include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate and cyclodextrin. Proper fluidity is maintained, for example, by the use of coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants.

[0257] The dosage of a composition comprising at least one compound described herein will vary depending on the condition of the patient (eg, human), ie, the stage of the disease, general health, age, and other factors.

[0258] The pharmaceutical composition is administered in a manner appropriate for the disease to be treated (or prevented). The appropriate dose, as well as the appropriate duration and frequency of administration, will be determined by factors such as the condition of the patient, the type and severity of the patient's disease, the specific form of the active ingredient, and the method of administration. In general, the appropriate dose and treatment regimen provides the composition in an amount sufficient to provide therapeutic and / or prophylactic benefits (e.g., improved clinical outcomes such as more frequent complete or partial remissions, longer disease-free and / or overall survival, or reduced severity of symptoms). The optimal dose is generally determined using experimental models and / or clinical trials. In some embodiments, the optimal dose depends on the patient's body type, weight, or blood volume.

[0259] Oral administration is generally performed at a dose of about 1.0 mg to about 1000 mg, 1 to 4 times a day.

[0260] The dose may be repeated depending on the pharmacokinetic parameters of the dosage formulation and the route of administration used.

[0261] It is particularly convenient to formulate the composition into dosage unit forms for ease of administration and uniformity of dosage. As used herein, dosage unit forms refer to physically discrete units suitable as unitary dosages for the mammalian subject to be treated, each unit containing a predetermined amount of active compound calculated to produce the desired therapeutic effect associated with the required pharmaceutical carrier. The specifications for dosage unit forms are dictated by and directly depend on (a) the inherent characteristics of the TYK2 pseudokinase ligand and the specific therapeutic effect to be achieved, and (b) the inherent limitations in the art of compounding such active compounds for the treatment of individual sensitivities. The specific dose may be easily calculated by those skilled in the art according to, for example, the approximate body weight or body surface area of ​​the patient, or the volume of the body space to be occupied. The dose is also calculated according to the specific route of administration selected. Further refinements to the calculations required to determine the appropriate dose for treatment are routinely performed by those skilled in the art. Such calculations may be performed by those skilled in the art without undue experimentation, taking into account the TYK2 pseudokinase ligand activity disclosed herein in the assay preparation of target cells. The exact dosage regimen is determined in conjunction with standard dose-response studies. It is understood that the amount of composition actually administered will be determined by the medical practitioner taking into account the relevant circumstances, including the disease being treated, the choice of composition to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration.

[0262] The toxicity and therapeutic efficacy of such TYK2 pseudokinase ligands can be determined, for example, by LD 50 (a dose lethal to 50% of the population) and ED 50 The dose that is therapeutically effective in 50% of the population can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio between toxic and therapeutic effects is the therapeutic index, which is the LD 50 / ED 50The therapeutic index can be expressed as a ratio of TYK2 pseudokinase ligands that exhibit large therapeutic indices. TYK2 pseudokinase ligands that exhibit toxic side effects may be used, but care must be taken to design a delivery system that targets such inhibitors to the site of affected tissue in order to reduce side effects by minimizing potential damage to uninfected cells.

[0263] The data obtained from cell culture assays and animal studies can be used to formulate a range of dosages for use in humans. Such dosages of TYK2 pseudokinase ligands can be administered at ED 100 mg / kg with little or no toxicity. 50 Preferably, the therapeutically effective dose will be within a blood concentration range including the IC50 / IC100 concentration range. This dosage may vary within this range depending upon the dosage form and route of administration utilized. For TYK2 pseudokinase ligands used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. The desired IC50 / IC100 concentration range is preferably within a blood concentration range including the IC50 / IC100 concentration range. 50 Doses may be formulated in animal models to achieve a circulating plasma concentration range (the concentration of TYK2 pseudokinase ligand that achieves half-maximal inhibition of symptoms) that includes. Such information can be used to more accurately determine useful doses in humans. Plasma concentrations can be measured, for example, by high performance liquid chromatography. EXAMPLES

[0264] The following examples are provided for illustrative purposes and are not intended to limit the scope of the claims provided herein.All references cited in these examples and throughout this specification are incorporated herein by reference for all legal purposes provided thereby.The starting materials and reagents used in the synthesis of the compounds described herein can be synthesized or obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, Acros Organics, Fluka, and Fischer Scientific.

[0265] Standard abbreviations and acronyms are used herein as defined in J. Org. Chem. 2007 72(1):23A-24A. Other abbreviations and acronyms used herein are as follows:

[0266] [Table 1] EXAMPLES

[0267] Synthesis of 5-chloro-N-(4-methoxybenzyl)-N-methyl-3-nitropyrazolo[1,5-a]pyrimidin-7-amine (Intermediate 1E)

[0268] [ka]

[0269] Step 1: To a solution of 1A (100 g, 1.17 mol) and diethyl malonate (214 g, 1.34 mol) in EtOH (500 mL) was added EtONa (20% w / w in EtOH, 819 g, 2.41 mol). The reaction mixture was stirred under N2 at 80° C. overnight. The solvent was removed under vacuum. The residue was diluted with water (2000 mL) and acidified with 1N HCl to pH ∼2. The precipitate was collected by filtration to give 1B (125 g, 69%) as a brown solid.

[0270] Step 2: To a solution of 1B (100 g, 1.7 mmol) in POCl3 (500 mL) was added Et2NPh (167.8 g, 1.12 mol, 1.7 equiv) below 30 °C. The mixture was stirred at 90 °C for 5.0 h. The reaction mixture was poured into ice water (3000 mL) and extracted with EtOAc (3 x 1000 mL). The combined organic layers were washed with saturated NaHCO3 and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column to give 119dC (90 g, 73%) as a white solid.

[0271] Step 3: To sulfuric acid (600 mL, concentrated) in a 2000 mL flask at -10°C, nitric acid (300 mL, 70%) was added dropwise over 30 min. The temperature was maintained below 0°C while solid 1C (100 g) was added in small portions. The mixture was stirred at 0°C for an additional 2.0 h. The mixture was poured into ice water (3.0 L) and extracted with DCM (3 x 1 L). The combined organic layers were washed with saturated NaHCO3 and brine, dried over Na2SO4, filtered and concentrated. The residue was triturated with petroleum ether / EtOAc (300 mL, 5 / 1, v / v). The solid was collected by filtration and dried under vacuum to give compound 1D (96 g, 77%) as a yellow solid.

[0272] Step 4: To a solution of compound 1D (100 g, 430 mmol) in dioxane (1500 mL) was added PMBNHCH3 (65 g, 430 mmol) and TEA (87.0 g, 860 mol). The mixture was stirred at 90° C. for 1.0 h. The mixture was diluted with DCM (3000 mL) and washed with brine. The organic phase was dried over Na2SO4 and concentrated under vacuum. The residue was triturated with petroleum ether / EtOAc (1500 mL, 10 / 1, v / v). The solid was collected by filtration and dried under vacuum to give 5-chloro-N-(4-methoxybenzyl)-N-methyl-3-nitropyrazolo[1,5-a]pyrimidin-7-amine (1E) (130 g, 87%) as a yellow solid. LCMS: 248.0 [M+H] + . EXAMPLES

[0273] Synthesis of 7-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-amine (Intermediate 2E)

[0274] [ka]

[0275] Step 1: To a solution of 2A (100.0 g, 0.769 mol) in AcOH (800 mL) was added HNO3 / AcOH (200 mL, v / v=1 / 1) dropwise. The mixture was stirred at 10° C. for 90 min and then poured into ice water (4 L). The solid was collected by filtration and washed with a small amount of water to give 2B (125 g, 93%), which was used in the next step without further purification.

[0276] Step 2: To a solution of 2B (125.0 g, 0.714 mol) in DMF (800 mL) at 25 °C, 2-bromoethanol (220.0 g, 1.785 mol) and DIPEA (454.0 g, 3.570 mol) were added. The mixture was stirred at 120 °C for 2 h. The reaction solution was diluted with water (8 L), extracted with EtOAc (4 L), and dried over Na2SO4. The crude product was purified by column chromatography to give 2C (116 g, 73%) as a yellow oil.

[0277] Step 3: To a solution of 2C (116 g, 0.530 mol) in DMF (600 mL) was added Cs2CO3 (460.0 g, 1.589 mol), and the mixture was then warmed at 80 °C for 1 h. The mixture was poured into ice water (5 L) and extracted with EtOAc (3 L). The solvent was removed under reduced pressure, and the residue was purified by column chromatography to give 2D (85 g, 85%) as a pale yellow solid.

[0278] Step 4: To a solution of 2D (70.0 g, 0.352 mol) in EtOAc (500 mL) at 25 °C was added Pd / C (7.0 g). The resulting mixture was stirred at room temperature under H2 atmosphere for 14 h. The mixture was filtered and washed with EtOAc. The organic phase was collected and the solvent was removed under reduced pressure to give 7-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-amine (2E) (45 g, 75%) as a brown oil. EXAMPLES

[0279] Synthesis of phenyl((1R,2S)-2-fluorocyclopropyl)carbamate (intermediate 3C)

[0280] [ka]

[0281] To a solution of compound 3A (100 g, 405 mmol) in DCM (1000 mL) at -20°C was added TEA (122 g, 1.22 mol). To this mixture was added compound 3B (70 g, 445 mmol) over 30 min at -20°C. The mixture was stirred at -78°C for 2.0 h. The reaction mixture was washed with saturated NaHCO3 and brine, the organic phase was dried over Na2SO4 and concentrated in vacuo to give phenyl ((1R,2S)-2-fluorocyclopropyl)carbamate (3C) (70 g, 91%) as a brown solid. LCMS: 196.0 [M+H] + . EXAMPLES

[0282] Synthesis of 1-(5-((7-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea (5)

[0283] [ka]

[0284] Step 1: To a solution of 1E (100 g, 288 mmol) and 2E (57 g, 345 mmol) in dry 1,4-dioxane (3000 mL) under N2, Cs2CO3 (141 g, 432 mmol), Pd(OAc)2 (5.2 g, 23.3 mmol), and BINAP (28.6 g, 46.6 mmol) were added. After stirring at 115 °C overnight, the reaction mixture was cooled to room temperature and diluted with hexanes (3000 mL). The solid was collected by filtration and washed twice with 1500 mL (50% hexanes in DCM). The solid was suspended in 5000 mL water and stirred for 1 h. The solid was collected by filtration and dried under vacuum to give compound 2 (90 g, 65%) as a brown solid.

[0285] Step 2: To a solution of compound 2 (70 g, 145 mmol) in NMP (2000 mL) was added saturated NH4Cl (aq., 1000 mL) and Fe (92.8 g, 1.45 mol). After stirring at 80 °C for 5.0 h, the reaction mixture was cooled to room temperature and filtered. The filtrate was poured into water (20 L) and the solid was collected by filtration. The solid was dissolved in DCM (ca. 1500 mL) and flashed through a short silica gel column, and the column was washed with an additional 3000 mL of DCM / MeOH = 30 / 1. The organic phase was concentrated under vacuum. The residue was triturated with EtOH / MeCN (2000 mL, 5 / 1, v / v). The solid was collected by filtration and dried under vacuum to give compound 3 (46 g, 71%) as a brown solid.

[0286] Step 3: To a solution of compound 3 (86 g, 0.19 mol, 1.0 equiv.) in DMF (800 mL) was added 3C (44.7 g, 0.23 mol, 1.3 eq.) and TEA (38.6 g, 0.38 mol, 2 eq.). After stirring at 80° C. for 2 h, the reaction mixture was cooled to room temperature and poured into water (8000 mL). The solid was collected by filtration and dried under vacuum. The residue was triturated with EtOH / MeCN (1200 mL, 5 / 1, v / v). The solid was collected by filtration and dried under vacuum to give compound 4 (75 g, 71%) as a brown solid.

[0287] Step 4: To a solution of compound 4 (118 g, 0.21 mol, 1.0 eq.) in DCM (1200 mL) was added triethylsilane (37.3 g, 0.32 mol, 1.5 eq.). After stirring for 10 min, TFA (240 mL) was added to the mixture and the reaction solution was stirred at room temperature for 0.5 h. TfOH (60 mL) was added and the reaction solution was stirred at room temperature for an additional 2 h. The reaction mixture was poured into saturated NaHCO3 (30 mL). The solid was collected by filtration and dried under vacuum. The solid was triturated with EtOH (500 mL) and collected by filtration. The solid was triturated with EtOAc (2 x 30 mL). The solid was collected by filtration and dried under vacuum to give 1-(5-((7-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea (5) (80 g, 86%) as a yellow solid. LCMS: 432.1 [M+H] + . EXAMPLES

[0288] Synthesis of 1-(5-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-methylurea (7)

[0289] [ka]

[0290] Step 1: To sulfuric acid (9 mL, concentrated) in a 100 mL flask at -10°C was added nitric acid (4.5 mL, 70%) dropwise over 2 min. Solid 5,7-dichloropyrazolo[1,5-a]pyrimidine (AA) (1.0 g) was added portionwise. The resulting mixture was allowed to stir at 0°C for 6 h. LC / MS showed no starting material remained. 80 mL of ice water was added to the reaction and stirred at 0°C for 20 min. The mixture was extracted with DCM (3 x 60 mL) and washed with saturated NaHCO3 and brine. The solvent was removed in vacuuo to give 5,7-dichloro-3-nitropyrazolo[1,5-a]pyrimidine (1BB) (1.15 g) as a yellow solid, which was used without further purification.

[0291] Step 2: 5,7-Dichloro-3-nitropyrazolo[1,5-a]pyrimidine (1BB) (1.2 g, 1.0 eq) and TEA (0.624 g, 1.2 eq) were dissolved in DMF (12 mL). The solution was cooled at -30°C (hexane / dry ice) and then a solution of 1-(4-methoxyphenyl)-N-methylmethanamine (0.682 g, 0.98 eq) in DMF (2 mL) was added dropwise. The resulting mixture was stirred at -20°C for 15 min. The reaction mixture was poured into ice water (200 mL) and stirred for 5 min. The precipitate was collected by filtration, washed with water (2 x 20 mL) and dried in vacuum to give 5-chloro-N-(4-methoxybenzyl)-N-methyl-3-nitropyrazolo[1,5-a]pyrimidin-7-amine (1E) (1.68 g, 94%), which was used without further purification.

[0292] Step 3: 5-Chloro-N-(4-methoxybenzyl)-N-methyl-3-nitropyrazolo[1,5-a]pyrimidin-7-amine (1E) (1.68 g, 1.0 eq) was suspended in EtOH (100 mL). To this solution was added iron powder (4.0 g, 15 eq) and saturated aqueous NH4Cl (30 mL). The resulting mixture was warmed at 90° C. for 35 min. Excess iron powder was removed by filtration through a Celite pad. The solvent was concentrated in vacuo. The residue was dissolved in ethyl acetate (70 mL) and washed with NaHCO3 (sat.) and brine. The crude mixture was purified on silica gel to give 5-chloro-N7-(4-methoxybenzyl)-N7-methylpyrazolo[1,5-a]pyrimidin-3,7-diamine (1F) (1.4 g, 91%) as a yellow oil that solidified overnight.

[0293] Step 4: 5-Chloro-N7-(4-methoxybenzyl)-N7-methylpyrazolo[1,5-a]pyrimidine-3,7-diamine (1F) (120 mg, 1.0 eq) was dissolved in dry THF (8 mL) and cooled at 0° C. under N2. To this solution was added triphosgene (37 mg, 0.33 eq) and DIEA (54 mg, 1.1 eq). The resulting mixture was stirred at room temperature for 15 min. The reaction mixture was cooled in an ice-water bath and CH3NH2 (2 M in THF, 0.6 mL, 3.0 eq) was added at 0° C. The resulting mixture was stirred at room temperature for 5 min. The reaction mixture was diluted with DCM (50 mL) and washed with NaHCO3 (sat.) and brine. The crude product was purified by ISCO to give 1-(5-chloro-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-methylurea (1G) (114 mg, 80%).

[0294] Step 5: 1-(5-chloro-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-methylurea (1G) (100 mg, 1.0 eq), 2,3-dihydrobenzo[b][1,4]dioxin-5-amine (61 mg, 1.5 eq), Pd(OAc)2 (15 mg, 0.25 eq), BINAP (67 mg, 0.4 eq), and Cs2CO3 (156 mg, 1.8 eq) were combined in dry dioxane (8 mL). The mixture was bubbled under N2 for 5 min and the reaction was warmed at 115 °C in a sealed tube for 8 h. The reaction was diluted with DCM (50 mL) and washed with water and brine. The crude material was purified by ISCO silica gel column to give 1-(5-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-methylurea (6) (45 mg).

[0295] Step 6: To a solution of 1-(5-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-methylurea (6) (45 mg) in DCM (2 mL) was added anisole (0.1 mL) and TFA (0.5 mL). The resulting mixture was stirred at room temperature for 1 h. The solvent was removed in vacuo. The residue was dissolved in DCM (50 mL) and washed with NaHCO3 (sat) and brine. The crude mixture was purified by ISCO silica gel column to give 1-(5-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-methylurea (7) (22 mg, 64%) as a beige solid. LCMS: 370.4 (M+H). + . EXAMPLES

[0296] Synthesis of 1-(5-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)urea (10)

[0297] [ka]

[0298] Step 1: To a solution of 5-chloro-N7-(4-methoxybenzyl)-N7-methylpyrazolo[1,5-a]pyrimidine-3,7-diamine (1F) (150 mg, 1.0 eq) in dry THF (2 mL) was added TMSNCO (82 mg, 1.5 eq). The resulting mixture was warmed at 60° C. for 1 h. The solvent was removed in vacuo. The residue was suspended in MeOH (5 mL) and the mixture was warmed at 60° C. for 1 h. After cooling to room temperature, the solid precipitated and was collected by filtration to give 1-(5-chloro-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)urea (8) (120 mg, 70%), which was used without further purification.

[0299] Step 2: 1-(5-chloro-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)urea (120 mg, 1.0 eq), 2,3-dihydrobenzo[b][1,4]dioxin-5-amine (8) (76 mg, 1.5 eq), Pd(OAc)2 (12 mg, 0.15 eq), BINAP (42 mg, 0.2 eq), and Cs2CO3 (162 mg, 1.5 eq) were combined in dry dioxane (8 mL). The mixture was bubbled under N2 for 5 min and the reaction was warmed at 115 °C in a sealed tube for 8 h. The reaction was diluted with DCM (50 mL) and washed with water and brine. The crude material was purified by ISCO silica gel column to give 1-(5-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)urea (9) (39 mg, 25%).

[0300] Step 3: To a solution of 1-(5-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)urea (9) (39 mg) in DCM (2 mL) was added anisole (0.1 mL) and TFA (0.5 mL). The resulting mixture was stirred at room temperature for 1 h. The solvent was removed in vacuo. The residue was dissolved in DCM (50 mL) and washed with NaHCO3 (sat.) and brine. The crude mixture was purified on an ISCO silica gel column to give 1-(5-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)urea (10) (20 mg, 69%) as a beige solid. LCMS: 356.5 (M+H) + . EXAMPLES

[0301] Synthesis of 1-(5-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-((methyl-d3)amino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-methylurea (13)

[0302] [ka]

[0303] Step 1: 5,7-Dichloro-3-nitropyrazolo[1,5-a]pyrimidine (1BB) (500 mg, 1.0 eq) and TEA (0.26 g, 1.2 eq) were dissolved in DMF (8 mL). The solution was cooled at -20 °C (hexane-dry ice) and then CD3NH2.HCl (148 mg, 0.98 eq) was added. The resulting mixture was stirred at -20 °C for 1 h. The reaction mixture was diluted with ethyl acetate (80 mL), washed with water (3 x 50 mL) and washed with brine. The organic phase was dried over Na2SO4 and concentrated in vacuo to give 5-chloro-N-(methyl-d3)-3-nitropyrazolo[1,5-a]pyrimidin-7-amine (11) (400 mg) as a yellow solid, which was used without purification.

[0304] Step 2: To a solution of 5-chloro-N-(methyl-d3)-3-nitropyrazolo[1,5-a]pyrimidin-7-amine (11) (400 mg, 1.0 eq) in DMF (15 mL) was added K2CO3 (760 mg, 3.0 eq) and PMBCl (410 mg, 1.5 eq). The resulting mixture was stirred at room temperature for 2 days. The reaction mixture was diluted with ethyl acetate (100 mL), washed with water (3 x 60 mL) and washed with brine. The crude mixture was purified on a silica gel column to give 5-chloro-N-(4-methoxybenzyl)-N-(methyl-d3)-3-nitropyrazolo[1,5-a]pyrimidin-7-amine (12) (410 mg, 67%).

[0305] 1-(5-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-((methyl-d3)amino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-methylurea (13) was prepared from 5-chloro-N-(4-methoxybenzyl)-N-(methyl-d3)-3-nitropyrazolo[1,5-a]pyrimidin-7-amine (12) following the synthetic procedure outlined in steps 3-6 of Example 1. LCMS: 373.5 (M+H). + . EXAMPLES

[0306] Synthesis of 1-(5-((1-(6-methoxypyridazin-3-yl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-methylurea (17)

[0307] [ka]

[0308] Step 1: To a suspension of 3,6-dibromopyridazine (1.0 g, 1.0 eq) in MeOH (50 mL) was added K2CO3 (1.2 g, 2.0 eq). The resulting mixture was warmed in a sealed tube at 90 °C for 15 h. The solvent was removed in vacuo. The residue was dissolved in ethyl acetate and washed with water and brine to give 3-bromo-6-methoxypyridazine (14) (725 mg, 92%), which was used without further purification.

[0309] Step 2: Benzyl (2-oxo-1,2-dihydropyridin-3-yl)carbamate (900 mg, 1.0 eq), 3-bromo-6-methoxypyridazine (14) (700 mg, 1.0 eq), N1,N1,N2,N2-tetramethylethane-1,2-diamine (0.13 g, 0.3 eq), CuI (71 mg, 0.1 eq), and K2CO3 (1.1 g, 2.0 eq) were combined in dry dioxane (25 mL). The mixture was bubbled with N2 gas for 5 min. The resulting mixture was warmed at 100 °C in a sealed tube for 14 h. The reaction was diluted with ethyl acetate (100 mL) and washed with water (2 x 50 mL). The crude product was purified by silica gel column to give benzyl (1-(6-methoxypyridazin-3-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate (15) (362 mg, 27%).

[0310] Step 3: Benzyl (1-(6-methoxypyridazin-3-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate (15) (360 mg) was dissolved in MeOH (20 mL) and ethyl acetate (20 mL). To this solution was added Pd / C (10%, 72 mg). The mixture was hydrogenated with H2 (50 psi) for 5 h. The catalyst was removed by filtration. The solvent was removed in vacuo to give a beige solid. The solid was suspended in ethyl acetate (5 mL) and heated to reflux for 5 min. After cooling to room temperature, a white solid was precipitated. The solid was collected by filtration and dried in vacuo to give 3-amino-1-(6-methoxypyridazin-3-yl)pyridin-2(1H)-one (16) (149 mg, 67%).

[0311] 1-(5-((1-(6-methoxypyridazin-3-yl)-2-oxo-1,2-dihydropyridin-3-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-methylurea (17) was prepared from 3-amino-1-(6-methoxypyridazin-3-yl)pyridine-2(1H)-1 (16) following the synthetic procedure outlined in steps 4-6 of Example 1. LCMS: 437.5 (M+H). + . EXAMPLES

[0312] Synthesis of 1-(5-((2-methoxy-3-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-methylurea (19)

[0313] [ka]

[0314] Step 1: 3-Bromo-2-methoxyaniline (1.0 g, 1.0 eq), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.23 g, 1.2 eq), PdCl2(dppf) (0.38 g, 0.1 eq), and K2CO3 (1.3 g, 2 eq) were combined in dioxane (30 mL) and water (10 mL). The mixture was degassed by bubbling N2 gas for 5 min. The resulting mixture was warmed at 90 °C under N2 for 14 h. The mixture was diluted with ethyl acetate (150 mL) and washed with water (100 mL) and brine. The crude mixture was purified by silica gel column to give 2-methoxy-3-(1-methyl-1H-pyrazol-4-yl)aniline (18) (0.64 g, 63%) as a brown solid.

[0315] 1-(5-((2-Methoxy-3-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-methylurea (19) was prepared from 2-methoxy-3-(1-methyl-1H-pyrazol-4-yl)aniline (18) following the synthetic procedure outlined in steps 4-6 of Example 1. LCMS: 422.5 (M+H). + . EXAMPLES

[0316] (1 3 E,1 4 E)-1 7 Synthesis of -(methylamino)-4-oxa-2,7,9-triaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(1,3)-benzeneacyclononaphan-8-one (22)

[0317] [ka]

[0318] 5-Chloro-N7-(4-methoxybenzyl)-N7-methylpyrazolo[1,5-a]pyrimidine-3,7-diamine (1F) (250 mg, 1.0 eq) was dissolved in dry THF (15 mL) and cooled at 0° C. under N2. To this solution was added triphosgene (77 mg, 0.33 eq) and DIEA (112 mg, 1.1 eq). The mixture was stirred at room temperature for 15 min and then cooled in an ice-water bath. 3-(2-aminoethoxy)aniline (132 mg, 1.1 eq) was added to the reaction mixture at 0° C. The resulting mixture was stirred at room temperature for 15 min. The reaction mixture was diluted with DCM (60 mL) and washed with NaHCO3 (sat.) and brine. The crude material was purified by ISCO to give 1-(2-(3-aminophenoxy)ethyl)-3-(5-chloro-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)urea (20) (258 mg, 66%).

[0319] 1-(2-(3-aminophenoxy)ethyl)-3-(5-chloro-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)urea (20) (200 mg, 1.0 eq), Pd(OAc)2 (20 mg, 0.2 eq), BINAP (110 mg, 0.4 eq), and Cs2CO3 (215 mg, 1.5 eq) were combined in dry dioxane (25 mL). N2 gas was bubbled through the mixture for 5 min. The resulting mixture was warmed to 115 °C in a sealed tube for 8 h. The reaction was diluted with DCM (100 mL) and ethyl acetate (100 mL). The insoluble solids were removed by filtration. The filtrate was concentrated in vacuo to give a brown solid. The solid was suspended in DCM (20 mL) and the suspension was heated to reflux for 10 min. After cooling to room temperature, the remaining solid was collected by filtration, washed with DCM (2 x 5 mL) and dried in vacuo to give (1E,1E)-1-((4-methoxybenzyl)(methyl)amino)-4-oxa-2,7,9-triaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(1,3)-benzeneacyclononaphan-8-one (21) (75 mg, 40%) as a yellow solid.

[0320] (1E,1E)-1-((4-Methoxybenzyl)(methyl)amino)-4-oxa-2,7,9-triaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(1,3)-benzeneacyclononaphan-8-one (21) (75 mg) was suspended in DCM (4 mL) and anisole (0.2 mL) and TFA (1 mL) were added. The resulting mixture was stirred at room temperature for 30 min. The mixture was concentrated to give a brown oil. The brown oil was dissolved in DCM (100 mL) and washed with NaHCO3 (sat.) and brine. The organic phase was dried over Na2SO4 and concentrated in vacuo to give a solid which was washed with DCM (2 x 5 mL) to give (1 3 E,1 4 E)-1 7 -(Methylamino)-4-oxa-2,7,9-triaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(1,3)-benzeneacyclononaphan-8-one (22) (38 mg, 69%) was obtained. LCMS: 340.3 (M+H). + . EXAMPLES

[0321] (1 3 E,1 4 E)-1 7 Synthesis of -(methylamino)-2,6,8-triaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(1,3)-benzeneacyclooctaphan-7-one (25)

[0322] [ka]

[0323] 5-Chloro-N7-(4-methoxybenzyl)-N7-methylpyrazolo[1,5-a]pyrimidine-3,7-diamine (1F) (180 mg, 1.0 eq) was dissolved in dry THF (12 mL) and cooled at 0° C. under N2. To this solution was added triphosgene (55 mg, 0.33 eq) and DIEA (80 mg, 1.1 eq). The mixture was stirred at room temperature for 15 min and then cooled again in an ice-water bath. 3-(2-aminoethyl)aniline (85 mg, 1.1 eq) was added to the reaction mixture at 0° C. The resulting mixture was stirred at room temperature for 15 min. The reaction mixture was diluted with DCM (40 mL) and washed with NaHCO3 (sat.) and brine. The crude material was purified by ISCO to give 1-(3-aminophenethyl)-3-(5-chloro-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)urea (23) (165 mg, 61%).

[0324] 1-(3-aminophenethyl)-3-(5-chloro-7-((4-methoxybenzyl)(methyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)urea (23) (160 mg, 1.0 eq), Pd(OAc)2 (15 mg, 0.2 eq), BINAP (83 mg, 0.4 eq), and Cs2CO3 (165 mg, 1.5 eq) were combined in dry dioxane (25 mL). N2 gas was bubbled through the mixture for 5 min. The resulting mixture was warmed to 115 °C in a sealed tube for 8 h. The reaction was diluted with DCM (100 mL) and ethyl acetate (100 mL). The insoluble solids were removed by filtration. The filtrate was concentrated in vacuo to give a brown solid. The solid was suspended in DCM (20 mL) and the suspension was heated to reflux for 10 min. After cooling to room temperature, the remaining solid was collected by filtration, washed with DCM (2 x 5 mL) and dried in vacuo to give (1E,1E)-1-((4-methoxybenzyl)(methyl)amino)-2,6,8-triaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(1,3)-benzeneacyclooctaphan-7-one (24) (56 mg, 38%) as a yellow solid.

[0325] (1E,1E)-1-((4-Methoxybenzyl)(methyl)amino)-2,6,8-triaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(1,3)-benzeneacyclooctaphan-7-one (24) (56 mg) was suspended in DCM (4 mL) and anisole (0.2 mL) and TFA (1 mL) were added. The resulting mixture was stirred at room temperature for 30 min. The mixture was concentrated to give a brown oil. The brown oil was dissolved in DCM (100 mL) and washed with NaHCO3 (sat.) and brine. The organic phase was dried over Na2SO4 and concentrated in vacuo to give a solid which was washed with DCM (2 x 5 mL) to give (1 3 E,1 4 E)-1 7 -(Methylamino)-2,6,8-triaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(1,3)-benzeneacyclooctaphan-7-one (25) (30 mg, 73%) was obtained. LCMS: 324.6 (M+H). + .

[0326] Compounds 26-187 were prepared by procedures similar to those described in the above examples.

[0327] [Table 2-1]

[0328] [Table 2-2]

[0329] [Table 2-3]

[0330] [Table 2-4]

[0331] [Table 2-5]

[0332]

Table 2-6

[0333]

Table 2-7

[0334]

Table 2-8

[0335]

Table 2-9

[0336]

Table 2-10

[0337]

Table 2-11

[0338]

Table 2-12

[0339]

Table 2-13

[0340]

Table 2-14

[0341]

Table 2-15

[0342] [Table 2-16]

[0343] [Table 2-17]

[0344] [Table 2-18]

[0345] [Table 2-19]

[0346] [Table 2-20]

[0347] [Table 2-21]

[0348] [Table 2-22] EXAMPLES

[0349] Costimulation assay for total hemolysis; JAK2:GM-CSF stimulated STAT5 phosphorylation and JAK1 / TYK2 stimulated STAT1 phosphorylation assay

[0350] Human blood lysis using Abcam's RBC lysis buffer Dilute RBC lysis buffer to 1X in distilled water. Add 2 mL of blood to 38 mL of 1X RBC lysis buffer. Incubate in the dark for 15 minutes at room temperature. Spin at 300g for 5 minutes and collect pellet. Re-lyse if necessary. Resuspend pellet in 5 mL of cRPMI.

[0351] Compound and cytokine treatment 80 μL of lysed human blood is aliquoted and placed into wells of a 96-deep-well plate. 10 μL of compounds at various concentrations (10x concentrated) are placed into all wells, except for the control (unstimulated and unstained), which are mixed with the aid of a 100 μL multichannel. 10 μL of RPMI medium is added to the controls. See attachment for compound dilutions and dilution ranges. Incubation is performed for 1 hour at 37°C in a water bath or CO2 incubator. 10 μL of (10x concentrated) cytokine mixture (GM-CSF and IFNa) (final concentration of GM-CSF 10 ng / mL, final concentration of IFNa 100 ng / mL) is placed into each well, except for the unstimulated and unstained control, which are incubated for 20 minutes at 37°C in a water bath.

[0352] RBC lysis and fixation Add 900μL of pre-warmed 1X Fix / Lyse solution (provided), mix using the 1000μL multichannel as appropriate, and incubate in the water bath for a further 10 minutes (including addition time) at 37°C. Centrifuge at 800xg for 5 minutes at 40°C, remove 900μL of supernatant, and add 900μL of 1X PBS. Centrifuge at 800xg for 5 minutes at 40°C, remove 900μL of supernatant. Wash once more with 900μL of PBS (optional) and resuspend pellet in 100μL of PBS.

[0353] Permeabilization The pellet is broken down by gentle tapping and resuspended in 1000 μL of BD Phosflow Perm Buffer III and the plate is incubated on ice for 30 minutes. The plate is centrifuged at 800×g for 5 minutes at 40° C. Wash two more times with 1000 μL of BD Pharmingen staining buffer.

[0354] Antibody treatment Break up the pellet by tapping gently. Resuspend the pellet in 100 μL staining buffer and add 5 μL pSTAT5_AF488 Ab and 5 μL pSTAT1_PE to all wells except the unstained control, mix using the 200 μL multichannel as appropriate, and incubate overnight at 40°C. Add 900 μL wash buffer and centrifuge at 1800 rpm for 3 minutes at 40°C. Wash once more with 1000 μL BD Pharmingen staining buffer. Finally, resuspend the pellet in 300 μL BD Pharmingen staining buffer. Transfer the cells to a 96-well v-bottom plate and acquire the cells in a Beckman Coulter CytExpert. Acquire the cells in a flow cytometer and keep the threshold at 250. The cell concentration should not exceed 100-500 cells / μL. Acquire at least 5,000-10,000 cells.

[0355] attached Preparation of reagents RPMI 1640 complete medium: RPMI 1640 medium + 10% FBS.

[0356] Cytokine dilutions: 1) 100 μg / mL GM-CSF stock. Prepare intermediate dilution 1 μg / mL by adding 2 μL of stock to 198 μL of cRPMI. Further dilute to 100 ng / mL by adding 100 μL of intermediate stock to 900 μL of cRPMI. 2) 200 μg / mL IFNa stock. Dilute IFNa stock 1:200 by adding 5 μL of stock to 1000 μL of 100 ng / mL GM-CSF working stock as above to obtain a working stock of 1000 ng / mL IFNa and 100 ng / mL GM-CSF (10x). Store this on ice until use.

[0357] Preparation of Lyse / Fix Buffer: Dilute 5X Lyse / Fix Buffer to 1X using MQ water and store at 37° C. until use.

[0358] BD Phosflow perm buffer III: Store on ice / refrigerator.

[0359] [Table 3]

[0360] I C 50 The values ​​are shown in the table below.

[0361] [Table 4-1]

[0362] [Table 4-2] EXAMPLES

[0363] Human liver microsome stability assay

[0364] Microsomal stability assays were performed at 37°C in 96-well microtiter plates. Reaction mixtures (25 μL) contained final concentrations of 1 μM test compound, 0.5 mg / mL human liver microsomal protein, and 1 mM NADPH and / or 1 mM UDPGA (containing alamethicin) in 100 mM potassium phosphate buffer at pH 7.4 containing 3 mM MgCl2. At each time point (e.g., 0, 15, 30, and 60 min), 150 μL of quench solution (100% acetonitrile with 0.1% formic acid) containing the internal standard was transferred to each well. In addition to the 0 min control, a mixture containing the same components except for NADPH was also prepared as a negative control. Verapamil was used as a positive control to verify the performance of the assay. The plate was sealed, vortexed, and centrifuged at 4000 rpm for 15 min at 4°C. The supernatant was transferred to a new plate for LC / MS / MS analysis. A comparison of the microsomal stability data for the urea compounds described herein and the corresponding amide compounds is shown in Table 1. The urea compounds unexpectedly exhibited increased microsomal stability compared to the amide compounds.

[0365] [Table 5] EXAMPLES

[0366] Pharmacokinetics (PK) in rats Rat PK studies were performed in IV and PO groups. Three rats per group were used. The formulations were solution for the IV group and solution or suspension formulations for the oral group. Plasma samples were collected at 0.08, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 hours for the IV group and 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours for the PO group using K2EDTA as anticoagulant and analyzed by a fit for purpose LC-MS / MS method. Pharmacokinetic parameters were evaluated using the non-compartmental analysis module in Phoenix WinNonlin® (version 8.0). Maximum concentrations (Cmax) were obtained from the observed values. The urea compounds unexpectedly showed increased Cmax compared to the amide compounds.

[0367] [Table 6] EXAMPLES

[0368] hepatocyte stability Human, rat, mouse or other animal hepatocytes can be used to assess the metabolic stability of compounds and predict intrinsic clearance. Human LiverPool™ 20-donor and animal cryopreserved hepatocytes were obtained from Bioreclamation IVT.

[0369] Cryopreserved hepatocytes were removed from the liquid nitrogen tank and thawed in a 37°C water bath. Once the cells were detached from the vial walls, they were decanted into 48 mL of warm HT medium. The cells were centrifuged at 420 rpm (50 g) for 4 minutes. After removing the supernatant, the pellet was resuspended in warm DMEM medium. The cell density was counted by hemocytometer.

[0370] The assay was performed in a 96-well microtiter plate. Compound 5 was incubated with hepatocytes for 0, 60, 120, and 180 min at 37°C. The reaction mixture (50 μL) contained a final concentration of 1 μM test compound, 500,000 cells / mL hepatocytes in DMEM medium. At each time point (e.g., 0, 1, 2, and 3 h), 200 μL of quench solution (100% acetonitrile with 0.1% formic acid) containing an internal standard was transferred to each well. Midazolam was used as a positive control to verify the performance of the assay. The plate was sealed and centrifuged at 4000 rpm for 15 min at 4°C. The supernatant was transferred to a new plate for LC / MS / MS analysis.

[0371] All samples were analyzed by LC / MS / MS using an AB Sciex API 4000 instrument connected to a Shimadzu LC-20AD LC pump system. Analytical samples were separated using a Waters Atlantis T3 dC18 reversed-phase HPLC column (20 mm x 2.1 mm) at a flow rate of 0.5 mL / min. The mobile phase consisted of 0.1% formic acid in water (solvent A) and 0.1% formic acid in 100% acetonitrile (solvent B).

[0372] The extent of metabolism was calculated as the disappearance of the test compound and compared to a 0 min control reaction incubation. Initial rates with respect to compound concentration were calculated and used to determine t values ​​and subsequently intrinsic clearance, CLint = (0.693)(1 / t(min))(mL incubation / million cells). As shown in Table 3, the urea compound (compound 5) unexpectedly exhibited greater metabolic stability compared to the corresponding amide compound.

[0373] [Table 7]

[0374] The examples and embodiments described herein are for illustrative purposes only, and in some embodiments, various modifications and variations will fall within the scope of the disclosure and the scope of the appended claims.

Claims

1. A compound having the structure of formula (I') or a pharma- ceutically acceptable salt or solvate thereof: 【Chemistry 1】 During the ceremony, X is N; Y is, 【Chemistry 2】 and L １ is -N(R ９ ) - and R １ teeth, 【Chemistry 3】 and R ２ is hydrogen, R ３ , and R ４ are independently hydrogen, C １ -C ６ Alkyl, and C １ -C ６ is selected from deuteroalkyl, R ５ is hydrogen, R ６ is hydrogen, R ８ is hydrogen, R ９ is hydrogen, The compound, or a pharma- ceutically acceptable salt or solvate thereof.

2. The Y is 【Chemistry 4】 2. The compound of claim 1, wherein:

3. The R ３ and the above R ４ are independently hydrogen and C １ -C ６ 2. The compound of claim 1, or a pharma- ceutically acceptable salt or solvate thereof, wherein: R is selected from the group consisting of alkyl, aryl, aryl, arylsulfates ...

4. The R ３ is hydrogen, and the R ４ C １ -C ６ 4. The compound of claim 3, or a pharma- ceutically acceptable salt or solvate thereof, wherein: R is an alkyl group; 5. The compound of claim 1, or a pharma- ceutically acceptable salt or solvate thereof, wherein R3 is hydrogen and R4 is C1-C6 deuteroalkyl.

6. below 【Chemistry 5】 2. The compound of claim 1, which is a compound selected from:

7. A structure of the formula: 【Chemistry 6】 2. The compound of claim 1, having the formula:

8. 8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt or solvate thereof, and a pharma- ceutically acceptable excipient.

9. 13. Use of a compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treating an inflammatory or autoimmune disease in a patient in need of such treatment.

10. 10. The use according to claim 9, wherein the inflammatory or autoimmune disease is selected from rheumatoid arthritis, multiple sclerosis, psoriasis, lupus, bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, vitiligo, and atopic dermatitis.

Images